CleftGeneDB-Search

Gene: CCN2

Basic information

Tag	Content
Uniprot ID	P29279; E1P578; Q6LCY0; Q96A79; Q96QX2; Q9UDL6;
Entrez ID	1490
Genbank protein ID	AAA75378.1; AAA91279.1; AAS55639.1; AAQ95223.1; CAG46559.1; EAW48038.1; EAW48039.1; AAK60505.1; AAK60507.1; CAA63267.1; AAV38598.1; CAA55544.1; AAK60506.1; AAV38597.1;
Genbank nucleotide ID	NM_001901.2
Ensembl protein ID	ENSP00000356954
Ensembl nucleotide ID	ENSG00000118523
Gene name	CCN family member 2
Gene symbol	CCN2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.
Sequence	MTAASMGPVR VAFVVLLALC SRPAVGQNCS GPCRCPDEPA PRCPAGVSLV LDGCGCCRVC 60 AKQLGELCTE RDPCDPHKGL FCHFGSPANR KIGVCTAKDG APCIFGGTVY RSGESFQSSC 120 KYQCTCLDGA VGCMPLCSMD VRLPSPDCPF PRRVKLPGKC CEEWVCDEPK DQTVVGPALA 180 AYRLEDTFGP DPTMIRANCL VQTTEWSACS KTCGMGISTR VTNDNASCRL EKQSRLCMVR 240 PCEADLEENI KKGKKCIRTP KISKPIKFEL SGCTSMKTYR AKFCGVCTDG RCCTPHRTTT 300 LPVEFKCPDG EVMKKNMMFI KTCACHYNCP GDNDIFESLY YRKMYGDMA 349

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	CCN2	281103	O18739		Bos taurus	Prediction	More>>
1:1 ortholog	CCN2	476202	J9NTX8		Canis lupus familiaris	Prediction	More>>
1:1 ortholog	CCN2	102191048	A0A452G077		Capra hircus	Prediction	More>>
1:1 ortholog	CCN2	1490	P29279		Homo sapiens	Prediction	More>>
1:1 ortholog	Ccn2	14219	P29268	CPO	Mus musculus	Publication	More>>
1:1 ortholog	CCN2		H2QTR1		Pan troglodytes	Prediction	More>>
1:1 ortholog	CCN2		F1S3P6		Sus scrofa	Prediction	More>>
1:1 ortholog	Ccn2	64032	Q9R1E9		Rattus norvegicus	Prediction	More>>
1:1 ortholog	ccn2a	321449	Q5RI33		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1046152495	p.Ala4Thr	missense variant	-	NC_000006.12:g.131951163C>T	TOPMed,gnomAD
rs1046152495	p.Ala4Ser	missense variant	-	NC_000006.12:g.131951163C>A	TOPMed,gnomAD
rs1475978750	p.Met6Val	missense variant	-	NC_000006.12:g.131951157T>C	gnomAD
rs1377436829	p.Gly7Ser	missense variant	-	NC_000006.12:g.131951154C>T	gnomAD
rs771454878	p.Val9Ile	missense variant	-	NC_000006.12:g.131951148C>T	ExAC,gnomAD
rs1470016991	p.Arg10Cys	missense variant	-	NC_000006.12:g.131951145G>A	TOPMed,gnomAD
rs747737409	p.Val15Ile	missense variant	-	NC_000006.12:g.131951130C>T	ExAC,TOPMed,gnomAD
rs1435972521	p.Val15Ala	missense variant	-	NC_000006.12:g.131951129A>G	TOPMed,gnomAD
rs894933526	p.Leu17Ile	missense variant	-	NC_000006.12:g.131951124G>T	TOPMed,gnomAD
rs1054975818	p.Ala18Val	missense variant	-	NC_000006.12:g.131951120G>A	TOPMed,gnomAD
rs936577744	p.Cys20Gly	missense variant	-	NC_000006.12:g.131951115A>C	TOPMed
rs1301024616	p.Cys20Tyr	missense variant	-	NC_000006.12:g.131951114C>T	gnomAD
rs936577744	p.Cys20Arg	missense variant	-	NC_000006.12:g.131951115A>G	TOPMed
rs866471933	p.Ser21Asn	missense variant	-	NC_000006.12:g.131951111C>T	TOPMed
rs866471933	p.Ser21Ile	missense variant	-	NC_000006.12:g.131951111C>A	TOPMed
rs1371343788	p.Ser21Arg	missense variant	-	NC_000006.12:g.131951112T>G	gnomAD
rs1307860560	p.Arg22Gln	missense variant	-	NC_000006.12:g.131951108C>T	gnomAD
rs1405926925	p.Pro23Leu	missense variant	-	NC_000006.12:g.131950991G>A	TOPMed,gnomAD
rs530485396	p.Gln27Arg	missense variant	-	NC_000006.12:g.131950979T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs375793270	p.Ser30Arg	missense variant	-	NC_000006.12:g.131950969G>T	TOPMed,gnomAD
rs375793270	p.Ser30Arg	missense variant	-	NC_000006.12:g.131950969G>C	TOPMed,gnomAD
rs1245891260	p.Ser30Gly	missense variant	-	NC_000006.12:g.131950971T>C	TOPMed
rs1232637209	p.Gly31Trp	missense variant	-	NC_000006.12:g.131950968C>A	TOPMed
rs563027002	p.Arg34Gln	missense variant	-	NC_000006.12:g.131950958C>T	1000Genomes,TOPMed,gnomAD
rs563027002	p.Arg34Leu	missense variant	-	NC_000006.12:g.131950958C>A	1000Genomes,TOPMed,gnomAD
rs961009845	p.Pro36Leu	missense variant	-	NC_000006.12:g.131950952G>A	TOPMed
rs532271775	p.Pro36Ser	missense variant	-	NC_000006.12:g.131950953G>A	1000Genomes,ExAC,gnomAD
rs961009845	p.Pro36Arg	missense variant	-	NC_000006.12:g.131950952G>C	TOPMed
rs1038619364	p.Asp37Gly	missense variant	-	NC_000006.12:g.131950949T>C	TOPMed,gnomAD
rs1158575008	p.Asp37Asn	missense variant	-	NC_000006.12:g.131950950C>T	gnomAD
rs754049250	p.Asp37Glu	missense variant	-	NC_000006.12:g.131950948G>T	ExAC,TOPMed,gnomAD
rs754049250	p.Asp37Glu	missense variant	-	NC_000006.12:g.131950948G>C	ExAC,TOPMed,gnomAD
rs1013718997	p.Glu38Lys	missense variant	-	NC_000006.12:g.131950947C>T	TOPMed,gnomAD
rs1352520657	p.Pro39Ser	missense variant	-	NC_000006.12:g.131950944G>A	TOPMed
rs1472409252	p.Pro41Leu	missense variant	-	NC_000006.12:g.131950937G>A	TOPMed,gnomAD
rs1255400952	p.Arg42His	missense variant	-	NC_000006.12:g.131950934C>T	gnomAD
rs13212409	p.Arg42Cys	missense variant	-	NC_000006.12:g.131950935G>A	TOPMed
rs1189784188	p.Cys43Trp	missense variant	-	NC_000006.12:g.131950930G>C	gnomAD
rs894929214	p.Pro44Thr	missense variant	-	NC_000006.12:g.131950929G>T	TOPMed
rs1451944599	p.Pro44Leu	missense variant	-	NC_000006.12:g.131950928G>A	TOPMed
rs1285048164	p.Ala45Val	missense variant	-	NC_000006.12:g.131950925G>A	TOPMed,gnomAD
rs1213162662	p.Gly46Asp	missense variant	-	NC_000006.12:g.131950922C>T	gnomAD
rs1284317067	p.Leu49Phe	missense variant	-	NC_000006.12:g.131950914G>A	TOPMed,gnomAD
rs1334757394	p.Val50Ala	missense variant	-	NC_000006.12:g.131950910A>G	gnomAD
rs577763812	p.Asp52Glu	missense variant	-	NC_000006.12:g.131950903G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1288681557	p.Gly53Asp	missense variant	-	NC_000006.12:g.131950901C>T	gnomAD
rs1356462790	p.Gly53Arg	missense variant	-	NC_000006.12:g.131950902C>G	TOPMed,gnomAD
rs1256160317	p.Cys54Ter	stop gained	-	NC_000006.12:g.131950897G>T	TOPMed
rs1428867855	p.Gly55Ser	missense variant	-	NC_000006.12:g.131950896C>T	gnomAD
rs887245529	p.Cys56Tyr	missense variant	-	NC_000006.12:g.131950892C>T	TOPMed,gnomAD
rs887245529	p.Cys56Ser	missense variant	-	NC_000006.12:g.131950892C>G	TOPMed,gnomAD
rs1461041423	p.Cys57Ser	missense variant	-	NC_000006.12:g.131950890A>T	gnomAD
rs111779788	p.Arg58Cys	missense variant	-	NC_000006.12:g.131950887G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs111779788	p.Arg58Gly	missense variant	-	NC_000006.12:g.131950887G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1475512451	p.Val59Ile	missense variant	-	NC_000006.12:g.131950884C>T	gnomAD
rs1475512451	p.Val59Leu	missense variant	-	NC_000006.12:g.131950884C>G	gnomAD
rs1260715722	p.Ala61Thr	missense variant	-	NC_000006.12:g.131950878C>T	gnomAD
rs1185846352	p.Lys62Gln	missense variant	-	NC_000006.12:g.131950875T>G	TOPMed
rs1242405632	p.Gln63Glu	missense variant	-	NC_000006.12:g.131950872G>C	gnomAD
rs1220165793	p.Leu64Met	missense variant	-	NC_000006.12:g.131950869G>T	gnomAD
rs1331949021	p.Gly65Asp	missense variant	-	NC_000006.12:g.131950865C>T	gnomAD
rs1274542744	p.Glu66Asp	missense variant	-	NC_000006.12:g.131950861C>G	gnomAD
rs1235633404	p.Leu67Pro	missense variant	-	NC_000006.12:g.131950859A>G	gnomAD
rs771364910	p.Leu67Val	missense variant	-	NC_000006.12:g.131950860G>C	ExAC
rs1295271748	p.Glu70Gln	missense variant	-	NC_000006.12:g.131950851C>G	TOPMed,gnomAD
rs780986630	p.Glu70Asp	missense variant	-	NC_000006.12:g.131950849C>G	ExAC,gnomAD
rs780986630	p.Glu70Asp	missense variant	-	NC_000006.12:g.131950849C>A	ExAC,gnomAD
rs1295271748	p.Glu70Lys	missense variant	-	NC_000006.12:g.131950851C>T	TOPMed,gnomAD
rs749727188	p.Glu70Gly	missense variant	-	NC_000006.12:g.131950850T>C	ExAC
rs1289608424	p.Arg71His	missense variant	-	NC_000006.12:g.131950847C>T	TOPMed,gnomAD
rs768393319	p.Arg71Ser	missense variant	-	NC_000006.12:g.131950848G>T	ExAC,gnomAD
rs768393319	p.Arg71Cys	missense variant	-	NC_000006.12:g.131950848G>A	ExAC,gnomAD
rs1392325444	p.Asp72Tyr	missense variant	-	NC_000006.12:g.131950845C>A	gnomAD
rs1392325444	p.Asp72His	missense variant	-	NC_000006.12:g.131950845C>G	gnomAD
rs757875277	p.Asp75Tyr	missense variant	-	NC_000006.12:g.131950836C>A	ExAC,TOPMed,gnomAD
rs1430141143	p.Asp75Glu	missense variant	-	NC_000006.12:g.131950834G>T	gnomAD
rs757875277	p.Asp75Asn	missense variant	-	NC_000006.12:g.131950836C>T	ExAC,TOPMed,gnomAD
rs778832399	p.Pro76Leu	missense variant	-	NC_000006.12:g.131950832G>A	ExAC,TOPMed,gnomAD
rs750290405	p.Pro76Ser	missense variant	-	NC_000006.12:g.131950833G>A	ExAC
rs764203876	p.Lys78Thr	missense variant	-	NC_000006.12:g.131950826T>G	ExAC,gnomAD
rs753677977	p.Lys78Gln	missense variant	-	NC_000006.12:g.131950827T>G	ExAC
rs1213818204	p.Lys78Asn	missense variant	-	NC_000006.12:g.131950825C>A	gnomAD
rs934031221	p.Gly79Ala	missense variant	-	NC_000006.12:g.131950823C>G	TOPMed,gnomAD
rs752896023	p.Gly79Ser	missense variant	-	NC_000006.12:g.131950824C>T	ExAC,TOPMed,gnomAD
rs752896023	p.Gly79Cys	missense variant	-	NC_000006.12:g.131950824C>A	ExAC,TOPMed,gnomAD
rs759549246	p.Leu80Pro	missense variant	-	NC_000006.12:g.131950820A>G	ExAC,gnomAD
rs759549246	p.Leu80Gln	missense variant	-	NC_000006.12:g.131950820A>T	ExAC,gnomAD
rs767569105	p.Leu80Ile	missense variant	-	NC_000006.12:g.131950821G>T	ExAC,gnomAD
rs1369115003	p.Phe81Leu	missense variant	-	NC_000006.12:g.131950818A>G	gnomAD
rs763378768	p.Phe81Leu	missense variant	-	NC_000006.12:g.131950816G>T	ExAC,gnomAD
rs767059535	p.Phe81Cys	missense variant	-	NC_000006.12:g.131950817A>C	ExAC,TOPMed,gnomAD
rs773759696	p.Cys82Phe	missense variant	-	NC_000006.12:g.131950814C>A	ExAC,gnomAD
rs773759696	p.Cys82Tyr	missense variant	-	NC_000006.12:g.131950814C>T	ExAC,gnomAD
rs1463464110	p.His83Pro	missense variant	-	NC_000006.12:g.131950811T>G	TOPMed,gnomAD
rs746630581	p.His83Gln	missense variant	-	NC_000006.12:g.131950810G>T	ExAC,gnomAD
rs1463464110	p.His83Arg	missense variant	-	NC_000006.12:g.131950811T>C	TOPMed,gnomAD
rs7451102	p.His83Asp	missense variant	-	NC_000006.12:g.131950812G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs7451102	p.His83Asp	missense variant	-	NC_000006.12:g.131950812G>C	UniProt,dbSNP
VAR_027925	p.His83Asp	missense variant	-	NC_000006.12:g.131950812G>C	UniProt
rs7451102	p.His83Tyr	missense variant	-	NC_000006.12:g.131950812G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs775008083	p.Phe84Leu	missense variant	-	NC_000006.12:g.131950809A>G	ExAC
rs749248801	p.Gly85Val	missense variant	-	NC_000006.12:g.131950805C>A	ExAC,gnomAD
rs749248801	p.Gly85Asp	missense variant	-	NC_000006.12:g.131950805C>T	ExAC,gnomAD
rs778795621	p.Gly85Cys	missense variant	-	NC_000006.12:g.131950806C>A	ExAC,gnomAD
rs778795621	p.Gly85Ser	missense variant	-	NC_000006.12:g.131950806C>T	ExAC,gnomAD
rs752906843	p.Ser86Tyr	missense variant	-	NC_000006.12:g.131950802G>T	ExAC,gnomAD
rs755868110	p.Ser86Thr	missense variant	-	NC_000006.12:g.131950803A>T	ExAC
rs752906843	p.Ser86Phe	missense variant	-	NC_000006.12:g.131950802G>A	ExAC,gnomAD
rs767690353	p.Pro87Gln	missense variant	-	NC_000006.12:g.131950799G>T	ExAC,gnomAD
rs767690353	p.Pro87Leu	missense variant	-	NC_000006.12:g.131950799G>A	ExAC,gnomAD
rs751729070	p.Ala88Gly	missense variant	-	NC_000006.12:g.131950796G>C	ExAC
rs755104088	p.Ala88Thr	missense variant	-	NC_000006.12:g.131950797C>T	ExAC,TOPMed,gnomAD
rs1481919013	p.Asn89Ser	missense variant	-	NC_000006.12:g.131950793T>C	gnomAD
rs944116755	p.Arg90Cys	missense variant	-	NC_000006.12:g.131950791G>A	gnomAD
rs867106833	p.Arg90His	missense variant	-	NC_000006.12:g.131950790C>T	gnomAD
rs1335174629	p.Val94Met	missense variant	-	NC_000006.12:g.131950779C>T	gnomAD
rs372597924	p.Ala97Thr	missense variant	-	NC_000006.12:g.131950770C>T	ESP,TOPMed
rs1336918485	p.Ala97Gly	missense variant	-	NC_000006.12:g.131950543G>C	gnomAD
rs372597924	p.Ala97Ser	missense variant	-	NC_000006.12:g.131950770C>A	ESP,TOPMed
NCI-TCGA novel	p.Lys98Glu	missense variant	-	NC_000006.12:g.131950541T>C	NCI-TCGA
rs1284536513	p.Gly100Ser	missense variant	-	NC_000006.12:g.131950535C>T	gnomAD
rs562990573	p.Pro102Ser	missense variant	-	NC_000006.12:g.131950529G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs747157794	p.Ile104Val	missense variant	-	NC_000006.12:g.131950523T>C	ExAC,gnomAD
rs148642894	p.Gly106Ser	missense variant	-	NC_000006.12:g.131950517C>T	ESP,ExAC,TOPMed,gnomAD
rs1403859168	p.Gly106Asp	missense variant	-	NC_000006.12:g.131950516C>T	TOPMed
rs1323332598	p.Gly107Ser	missense variant	-	NC_000006.12:g.131950514C>T	gnomAD
rs758537392	p.Thr108Met	missense variant	-	NC_000006.12:g.131950510G>A	ExAC,gnomAD
rs750532772	p.Tyr110His	missense variant	-	NC_000006.12:g.131950505A>G	ExAC,TOPMed,gnomAD
rs779456819	p.Arg111His	missense variant	-	NC_000006.12:g.131950501C>T	ExAC,gnomAD
rs1371705903	p.Gly113Arg	missense variant	-	NC_000006.12:g.131950496C>T	gnomAD
rs754404946	p.Ser115Phe	missense variant	-	NC_000006.12:g.131950489G>A	ExAC,TOPMed
rs757658730	p.Ser115Thr	missense variant	-	NC_000006.12:g.131950490A>T	ExAC,gnomAD
rs962442276	p.Phe116Cys	missense variant	-	NC_000006.12:g.131950486A>C	TOPMed,gnomAD
rs764378587	p.Gln117Ter	stop gained	-	NC_000006.12:g.131950484G>A	ExAC,gnomAD
rs34385143	p.Ser118Asn	missense variant	-	NC_000006.12:g.131950480C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1271743207	p.Gly129Arg	missense variant	-	NC_000006.12:g.131950448C>T	gnomAD
rs772644537	p.Ala130Thr	missense variant	-	NC_000006.12:g.131950445C>T	ExAC,gnomAD
rs776713121	p.Val131Leu	missense variant	-	NC_000006.12:g.131950442C>A	ExAC,TOPMed,gnomAD
rs776713121	p.Val131Met	missense variant	-	NC_000006.12:g.131950442C>T	ExAC,TOPMed,gnomAD
rs776713121	p.Val131Leu	missense variant	-	NC_000006.12:g.131950442C>G	ExAC,TOPMed,gnomAD
rs374374828	p.Met134Val	missense variant	-	NC_000006.12:g.131950433T>C	ESP,ExAC,gnomAD
rs1324708871	p.Met134Lys	missense variant	-	NC_000006.12:g.131950432A>T	gnomAD
rs532894409	p.Pro135Leu	missense variant	-	NC_000006.12:g.131950429G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs746127819	p.Met139Thr	missense variant	-	NC_000006.12:g.131950417A>G	ExAC,TOPMed,gnomAD
rs772459582	p.Met139Val	missense variant	-	NC_000006.12:g.131950418T>C	ExAC,TOPMed,gnomAD
rs778822836	p.Asp140Glu	missense variant	-	NC_000006.12:g.131950413G>C	ExAC,gnomAD
NCI-TCGA novel	p.Arg142Ser	missense variant	-	NC_000006.12:g.131950409G>T	NCI-TCGA
rs1480590727	p.Arg142Cys	missense variant	-	NC_000006.12:g.131950409G>A	TOPMed
rs757366447	p.Pro146Ser	missense variant	-	NC_000006.12:g.131950397G>A	ExAC,gnomAD
rs1247364599	p.Pro146Arg	missense variant	-	NC_000006.12:g.131950396G>C	gnomAD
NCI-TCGA novel	p.Asp147Asn	missense variant	-	NC_000006.12:g.131950394C>T	NCI-TCGA
rs778311137	p.Pro151Ala	missense variant	-	NC_000006.12:g.131950382G>C	ExAC,gnomAD
rs756468635	p.Arg153Lys	missense variant	-	NC_000006.12:g.131950375C>T	ExAC,gnomAD
rs1205694127	p.Val154Ala	missense variant	-	NC_000006.12:g.131950372A>G	gnomAD
rs1458305011	p.Lys155Asn	missense variant	-	NC_000006.12:g.131950368C>G	TOPMed
rs1367648684	p.Cys160Tyr	missense variant	-	NC_000006.12:g.131950354C>T	gnomAD
rs959044702	p.Glu162Lys	missense variant	-	NC_000006.12:g.131950349C>T	TOPMed,gnomAD
rs959044702	p.Glu162Gln	missense variant	-	NC_000006.12:g.131950349C>G	TOPMed,gnomAD
rs757936868	p.Val165Met	missense variant	-	NC_000006.12:g.131950340C>T	ExAC,gnomAD
rs757936868	p.Val165Leu	missense variant	-	NC_000006.12:g.131950340C>G	ExAC,gnomAD
rs757936868	p.Val165Leu	missense variant	-	NC_000006.12:g.131950340C>A	ExAC,gnomAD
rs139453995	p.Asp167Glu	missense variant	-	NC_000006.12:g.131950332G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs761396200	p.Glu168Asp	missense variant	-	NC_000006.12:g.131950329C>A	ExAC,gnomAD
rs776692409	p.Lys170Arg	missense variant	-	NC_000006.12:g.131950324T>C	ExAC,TOPMed,gnomAD
rs1171937033	p.Asp171His	missense variant	-	NC_000006.12:g.131950322C>G	gnomAD
rs764190999	p.Gln172Glu	missense variant	-	NC_000006.12:g.131950319G>C	ExAC,TOPMed,gnomAD
rs764190999	p.Gln172Lys	missense variant	-	NC_000006.12:g.131950319G>T	ExAC,TOPMed,gnomAD
rs1385005797	p.Val174Ala	missense variant	-	NC_000006.12:g.131950312A>G	TOPMed,gnomAD
rs147441296	p.Val174Met	missense variant	-	NC_000006.12:g.131950313C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly176Trp	missense variant	-	NC_000006.12:g.131950307C>A	NCI-TCGA
rs1468505692	p.Gly176Val	missense variant	-	NC_000006.12:g.131950306C>A	gnomAD
rs1000248948	p.Pro177Leu	missense variant	-	NC_000006.12:g.131950303G>A	TOPMed
rs775379193	p.Ala180Glu	missense variant	-	NC_000006.12:g.131950294G>T	ExAC,gnomAD
rs759434407	p.Tyr182His	missense variant	-	NC_000006.12:g.131950158A>G	ExAC,TOPMed,gnomAD
rs1385269499	p.Arg183Gln	missense variant	-	NC_000006.12:g.131950154C>T	TOPMed,gnomAD
rs1356046175	p.Leu184Gln	missense variant	-	NC_000006.12:g.131950151A>T	TOPMed
COSM1073356	p.Glu185Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950149C>G	NCI-TCGA Cosmic
COSM5599363	p.Asp186Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950146C>T	NCI-TCGA Cosmic
rs1298892255	p.Thr187Lys	missense variant	-	NC_000006.12:g.131950142G>T	TOPMed
rs1166630038	p.Phe188Ser	missense variant	-	NC_000006.12:g.131950139A>G	gnomAD
rs1424115871	p.Gly189Ser	missense variant	-	NC_000006.12:g.131950137C>T	gnomAD
COSM1440519	p.Gly189Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950136C>T	NCI-TCGA Cosmic
rs200704146	p.Asp191Gly	missense variant	-	NC_000006.12:g.131950130T>C	1000Genomes
rs771227127	p.Pro192Thr	missense variant	-	NC_000006.12:g.131950128G>T	ExAC,gnomAD
rs565153897	p.Thr193Ala	missense variant	-	NC_000006.12:g.131950125T>C	ExAC,TOPMed,gnomAD
rs1317816082	p.Met194Val	missense variant	-	NC_000006.12:g.131950122T>C	TOPMed
COSM1440518	p.Ile195Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950119T>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Arg196SerPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.131950114_131950115insA	NCI-TCGA
rs773225479	p.Arg196Gly	missense variant	-	NC_000006.12:g.131950116T>C	ExAC,gnomAD
rs566555616	p.Arg196Thr	missense variant	-	NC_000006.12:g.131950115C>G	ExAC,gnomAD
rs781728789	p.Asn198Thr	missense variant	-	NC_000006.12:g.131950109T>G	ExAC,TOPMed,gnomAD
rs1313461069	p.Cys199Phe	missense variant	-	NC_000006.12:g.131950106C>A	TOPMed
rs1295345031	p.Leu200Val	missense variant	-	NC_000006.12:g.131950104G>C	gnomAD
rs768886233	p.Leu200Pro	missense variant	-	NC_000006.12:g.131950103A>G	ExAC,TOPMed,gnomAD
rs1298418697	p.Gln202Arg	missense variant	-	NC_000006.12:g.131950097T>C	gnomAD
rs1440339694	p.Thr204Arg	missense variant	-	NC_000006.12:g.131950091G>C	gnomAD
rs1458375028	p.Glu205Gly	missense variant	-	NC_000006.12:g.131950088T>C	gnomAD
rs1353655888	p.Ser207Arg	missense variant	-	NC_000006.12:g.131950083T>G	gnomAD
NCI-TCGA novel	p.Ser207ArgPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.131950081G>-	NCI-TCGA
NCI-TCGA novel	p.Ser207Asn	missense variant	-	NC_000006.12:g.131950082C>T	NCI-TCGA
rs187658120	p.Ala208Thr	missense variant	-	NC_000006.12:g.131950080C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1390472679	p.Thr212Ala	missense variant	-	NC_000006.12:g.131950068T>C	gnomAD
rs777353866	p.Cys213Arg	missense variant	-	NC_000006.12:g.131950065A>G	ExAC,TOPMed,gnomAD
rs142873474	p.Met215Ile	missense variant	-	NC_000006.12:g.131950057C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1198148430	p.Met215Thr	missense variant	-	NC_000006.12:g.131950058A>G	gnomAD
rs926301210	p.Ser218Phe	missense variant	-	NC_000006.12:g.131950049G>A	gnomAD
rs1193379334	p.Thr219Asn	missense variant	-	NC_000006.12:g.131950046G>T	gnomAD
rs1489124165	p.Arg220Gln	missense variant	-	NC_000006.12:g.131950043C>T	gnomAD
rs1202949995	p.Val221Ile	missense variant	-	NC_000006.12:g.131950041C>T	gnomAD
rs1202949995	p.Val221Leu	missense variant	-	NC_000006.12:g.131950041C>G	gnomAD
rs759220528	p.Thr222Ala	missense variant	-	NC_000006.12:g.131950038T>C	ExAC,TOPMed,gnomAD
COSM1073354	p.Thr222Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950037G>T	NCI-TCGA Cosmic
rs751421111	p.Asn223His	missense variant	-	NC_000006.12:g.131950035T>G	ExAC,TOPMed,gnomAD
rs766110787	p.Asp224His	missense variant	-	NC_000006.12:g.131950032C>G	ExAC,gnomAD
rs1303522975	p.Ala226Thr	missense variant	-	NC_000006.12:g.131950026C>T	gnomAD
COSM1073353	p.Ala226Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131950025G>A	NCI-TCGA Cosmic
rs1387256435	p.Ser227Phe	missense variant	-	NC_000006.12:g.131950022G>A	gnomAD
rs1387256435	p.Ser227Tyr	missense variant	-	NC_000006.12:g.131950022G>T	gnomAD
rs376817540	p.Cys228Phe	missense variant	-	NC_000006.12:g.131950019C>A	ESP,TOPMed
rs1226369163	p.Arg229Lys	missense variant	-	NC_000006.12:g.131950016C>T	gnomAD
rs1464236501	p.Glu231Gln	missense variant	-	NC_000006.12:g.131950011C>G	TOPMed
rs1361896958	p.Gln233Lys	missense variant	-	NC_000006.12:g.131950005G>T	gnomAD
rs1296234786	p.Gln233Pro	missense variant	-	NC_000006.12:g.131950004T>G	gnomAD
rs1411490974	p.Ser234Arg	missense variant	-	NC_000006.12:g.131950000G>T	gnomAD
rs1370947025	p.Arg235Cys	missense variant	-	NC_000006.12:g.131949999G>A	gnomAD
NCI-TCGA novel	p.Cys237Tyr	missense variant	-	NC_000006.12:g.131949992C>T	NCI-TCGA
rs769805883	p.Met238Val	missense variant	-	NC_000006.12:g.131949990T>C	ExAC,TOPMed,gnomAD
rs1452552929	p.Met238Arg	missense variant	-	NC_000006.12:g.131949989A>C	TOPMed
rs776995077	p.Pro241Ala	missense variant	-	NC_000006.12:g.131949981G>C	ExAC,TOPMed,gnomAD
rs776995077	p.Pro241Thr	missense variant	-	NC_000006.12:g.131949981G>T	ExAC,TOPMed,gnomAD
rs1434255647	p.Cys242Phe	missense variant	-	NC_000006.12:g.131949977C>A	gnomAD
NCI-TCGA novel	p.Glu243Lys	missense variant	-	NC_000006.12:g.131949975C>T	NCI-TCGA
rs769241756	p.Ala244Thr	missense variant	-	NC_000006.12:g.131949972C>T	ExAC,gnomAD
rs780414926	p.Asp245Asn	missense variant	-	NC_000006.12:g.131949969C>T	ExAC,TOPMed,gnomAD
rs772571408	p.Asp245Gly	missense variant	-	NC_000006.12:g.131949968T>C	ExAC,TOPMed,gnomAD
rs748894967	p.Glu247Gly	missense variant	-	NC_000006.12:g.131949962T>C	ExAC,gnomAD
rs1210373203	p.Glu247Gln	missense variant	-	NC_000006.12:g.131949963C>G	gnomAD
NCI-TCGA novel	p.Glu248Lys	missense variant	-	NC_000006.12:g.131949960C>T	NCI-TCGA
rs1305454118	p.Ile250Leu	missense variant	-	NC_000006.12:g.131949954T>G	TOPMed
rs777629332	p.Lys251Thr	missense variant	-	NC_000006.12:g.131949950T>G	ExAC,TOPMed,gnomAD
rs777629332	p.Lys251Arg	missense variant	-	NC_000006.12:g.131949950T>C	ExAC,TOPMed,gnomAD
COSM5169400	p.Lys251Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949949C>A	NCI-TCGA Cosmic
rs746904803	p.Lys252Glu	missense variant	-	NC_000006.12:g.131949560T>C	ExAC,TOPMed,gnomAD
rs138854270	p.Lys255Asn	missense variant	-	NC_000006.12:g.131949549C>A	ExAC,TOPMed,gnomAD
COSM450503	p.Arg258His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949541C>T	NCI-TCGA Cosmic
rs1207995947	p.Pro260Ser	missense variant	-	NC_000006.12:g.131949536G>A	gnomAD
rs757418221	p.Lys261Gln	missense variant	-	NC_000006.12:g.131949533T>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Lys261Ter	stop gained	-	NC_000006.12:g.131949533T>A	NCI-TCGA
NCI-TCGA novel	p.Pro265Ser	missense variant	-	NC_000006.12:g.131949521G>A	NCI-TCGA
rs1362630286	p.Ile266Val	missense variant	-	NC_000006.12:g.131949518T>C	gnomAD
rs929704507	p.Lys267Asn	missense variant	-	NC_000006.12:g.131949513C>G	TOPMed,gnomAD
rs754035771	p.Lys267Gln	missense variant	-	NC_000006.12:g.131949515T>G	ExAC,gnomAD
rs1369627643	p.Glu269Asp	missense variant	-	NC_000006.12:g.131949507C>G	gnomAD
rs1408985404	p.Gly272Asp	missense variant	-	NC_000006.12:g.131949499C>T	TOPMed
COSM3948027	p.Gly272Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949500C>A	NCI-TCGA Cosmic
rs1404121905	p.Thr274Asn	missense variant	-	NC_000006.12:g.131949493G>T	gnomAD
rs1393301194	p.Ser275Asn	missense variant	-	NC_000006.12:g.131949490C>T	gnomAD
rs1164240934	p.Thr278Lys	missense variant	-	NC_000006.12:g.131949481G>T	gnomAD
COSM3858331	p.Tyr279His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949479A>G	NCI-TCGA Cosmic
rs760727732	p.Arg280Gln	missense variant	-	NC_000006.12:g.131949475C>T	ExAC,TOPMed,gnomAD
rs1190773592	p.Ala281Gly	missense variant	-	NC_000006.12:g.131949472G>C	gnomAD
rs1388617650	p.Ala281Thr	missense variant	-	NC_000006.12:g.131949473C>T	gnomAD
COSM1073351	p.Phe283Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949465G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Cys284Phe	missense variant	-	NC_000006.12:g.131949463C>A	NCI-TCGA
NCI-TCGA novel	p.Gly285Glu	missense variant	-	NC_000006.12:g.131949460C>T	NCI-TCGA
rs776064732	p.Gly285Val	missense variant	-	NC_000006.12:g.131949460C>A	ExAC,gnomAD
rs768182416	p.Val286Ile	missense variant	-	NC_000006.12:g.131949458C>T	ExAC,TOPMed,gnomAD
rs759957908	p.Thr288Ala	missense variant	-	NC_000006.12:g.131949452T>C	ExAC,gnomAD
rs1338513702	p.Asp289His	missense variant	-	NC_000006.12:g.131949449C>G	TOPMed
rs1195073840	p.Gly290Ser	missense variant	-	NC_000006.12:g.131949446C>T	gnomAD
rs1195073840	p.Gly290Arg	missense variant	-	NC_000006.12:g.131949446C>G	gnomAD
rs1339618469	p.Arg291Ter	stop gained	-	NC_000006.12:g.131949443G>A	TOPMed,gnomAD
rs747768611	p.Arg291Gln	missense variant	-	NC_000006.12:g.131949442C>T	ExAC,gnomAD
rs776159645	p.Cys293Trp	missense variant	-	NC_000006.12:g.131949435G>C	ExAC,gnomAD
rs746566597	p.Thr294Ile	missense variant	-	NC_000006.12:g.131949433G>A	ExAC,gnomAD
rs768198949	p.Thr294Pro	missense variant	-	NC_000006.12:g.131949434T>G	ExAC,gnomAD
rs768198949	p.Thr294Ser	missense variant	-	NC_000006.12:g.131949434T>A	ExAC,gnomAD
rs1333400390	p.His296Arg	missense variant	-	NC_000006.12:g.131949427T>C	gnomAD
NCI-TCGA novel	p.His296GlnPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.131949426_131949427insT	NCI-TCGA
COSM4613137	p.His296ThrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.131949428G>-	NCI-TCGA Cosmic
rs1324602150	p.Thr298Pro	missense variant	-	NC_000006.12:g.131949422T>G	gnomAD
rs745824518	p.Thr299Pro	missense variant	-	NC_000006.12:g.131949419T>G	ExAC,gnomAD
rs778636424	p.Thr300Pro	missense variant	-	NC_000006.12:g.131949416T>G	ExAC,gnomAD
rs757019246	p.Pro302Ala	missense variant	-	NC_000006.12:g.131949410G>C	ExAC,TOPMed,gnomAD
rs1394533856	p.Pro302Leu	missense variant	-	NC_000006.12:g.131949409G>A	gnomAD
rs754080279	p.Val303Leu	missense variant	-	NC_000006.12:g.131949407C>A	ExAC,gnomAD
rs764293864	p.Glu304Gly	missense variant	-	NC_000006.12:g.131949403T>C	ExAC
rs1181016968	p.Phe305Leu	missense variant	-	NC_000006.12:g.131949399G>C	TOPMed,gnomAD
NCI-TCGA novel	p.Phe305Leu	missense variant	-	NC_000006.12:g.131949399G>T	NCI-TCGA
rs543282062	p.Lys306Gln	missense variant	-	NC_000006.12:g.131949398T>G	TOPMed
rs543282062	p.Lys306Glu	missense variant	-	NC_000006.12:g.131949398T>C	TOPMed
rs756191688	p.Pro308Ser	missense variant	-	NC_000006.12:g.131949392G>A	ExAC,TOPMed
NCI-TCGA novel	p.Pro308His	missense variant	-	NC_000006.12:g.131949391G>T	NCI-TCGA
rs756191688	p.Pro308Thr	missense variant	-	NC_000006.12:g.131949392G>T	ExAC,TOPMed
rs1253745497	p.Gly310Ser	missense variant	-	NC_000006.12:g.131949386C>T	gnomAD
NCI-TCGA novel	p.Gly310Cys	missense variant	-	NC_000006.12:g.131949386C>A	NCI-TCGA
rs141716795	p.Glu311Gly	missense variant	-	NC_000006.12:g.131949382T>C	ESP,ExAC,TOPMed,gnomAD
COSM483401	p.Glu311Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949383C>T	NCI-TCGA Cosmic
rs1430800186	p.Val312Phe	missense variant	-	NC_000006.12:g.131949380C>A	TOPMed
rs1345132458	p.Met317Ile	missense variant	-	NC_000006.12:g.131949363C>T	gnomAD
NCI-TCGA novel	p.Met317Leu	missense variant	-	NC_000006.12:g.131949365T>A	NCI-TCGA
rs752118942	p.Met317Val	missense variant	-	NC_000006.12:g.131949365T>C	ExAC,gnomAD
rs1383831556	p.Met318Arg	missense variant	-	NC_000006.12:g.131949361A>C	TOPMed
NCI-TCGA novel	p.Met318Val	missense variant	-	NC_000006.12:g.131949362T>C	NCI-TCGA
rs766790698	p.Phe319Val	missense variant	-	NC_000006.12:g.131949359A>C	ExAC,gnomAD
rs766790698	p.Phe319Leu	missense variant	-	NC_000006.12:g.131949359A>G	ExAC,gnomAD
rs1228356834	p.Ile320Thr	missense variant	-	NC_000006.12:g.131949355A>G	gnomAD
rs1348967024	p.Lys321Glu	missense variant	-	NC_000006.12:g.131949353T>C	gnomAD
NCI-TCGA novel	p.Lys321ArgPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.131949352T>-	NCI-TCGA
rs763283509	p.Thr322Pro	missense variant	-	NC_000006.12:g.131949350T>G	ExAC,gnomAD
rs1410630702	p.Cys323Tyr	missense variant	-	NC_000006.12:g.131949346C>T	gnomAD
rs760206555	p.Ala324Val	missense variant	-	NC_000006.12:g.131949343G>A	ExAC
rs768232580	p.Ala324Pro	missense variant	-	NC_000006.12:g.131949344C>G	ExAC,gnomAD
rs1332254757	p.Cys325Tyr	missense variant	-	NC_000006.12:g.131949340C>T	gnomAD
rs774929294	p.Tyr327Ter	stop gained	-	NC_000006.12:g.131949333G>T	ExAC,TOPMed,gnomAD
rs774929294	p.Tyr327Ter	stop gained	-	NC_000006.12:g.131949333G>C	ExAC,TOPMed,gnomAD
rs771598402	p.Asn328Ser	missense variant	-	NC_000006.12:g.131949331T>C	ExAC,TOPMed,gnomAD
rs1399636126	p.Asn328Lys	missense variant	-	NC_000006.12:g.131949330G>T	TOPMed
rs770759170	p.Gly331Arg	missense variant	-	NC_000006.12:g.131949323C>T	ExAC,TOPMed,gnomAD
rs749081361	p.Asp332Gly	missense variant	-	NC_000006.12:g.131949319T>C	ExAC,gnomAD
rs148327380	p.Asn333Ser	missense variant	-	NC_000006.12:g.131949316T>C	ESP,ExAC,TOPMed,gnomAD
rs756243018	p.Asp334Tyr	missense variant	-	NC_000006.12:g.131949314C>A	ExAC,gnomAD
rs1211808095	p.Asp334Gly	missense variant	-	NC_000006.12:g.131949313T>C	TOPMed,gnomAD
rs1036211794	p.Ile335Val	missense variant	-	NC_000006.12:g.131949311T>C	TOPMed
rs753000035	p.Glu337Gln	missense variant	-	NC_000006.12:g.131949305C>G	ExAC,TOPMed,gnomAD
rs371266547	p.Ser338Ter	stop gained	-	NC_000006.12:g.131949301G>T	ESP,ExAC,TOPMed,gnomAD
rs371266547	p.Ser338Leu	missense variant	-	NC_000006.12:g.131949301G>A	ESP,ExAC,TOPMed,gnomAD
COSM3777120	p.Ser338Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949302A>G	NCI-TCGA Cosmic
rs755120527	p.Tyr340Phe	missense variant	-	NC_000006.12:g.131949295T>A	ExAC,TOPMed,gnomAD
rs755120527	p.Tyr340Cys	missense variant	-	NC_000006.12:g.131949295T>C	ExAC,TOPMed,gnomAD
rs1052086665	p.Tyr341Ter	stop gained	-	NC_000006.12:g.131949291G>T	gnomAD
rs752098338	p.Tyr341Cys	missense variant	-	NC_000006.12:g.131949292T>C	ExAC,TOPMed,gnomAD
rs766862137	p.Arg342Gly	missense variant	-	NC_000006.12:g.131949290T>C	ExAC,TOPMed,gnomAD
rs763345161	p.Met344Ile	missense variant	-	NC_000006.12:g.131949282C>T	ExAC,gnomAD
NCI-TCGA novel	p.Tyr345Ter	stop gained	-	NC_000006.12:g.131949279G>T	NCI-TCGA
rs866211072	p.Gly346Arg	missense variant	-	NC_000006.12:g.131949278C>T	gnomAD
rs1286434015	p.Gly346Glu	missense variant	-	NC_000006.12:g.131949277C>T	gnomAD
NCI-TCGA novel	p.Asp347His	missense variant	-	NC_000006.12:g.131949275C>G	NCI-TCGA
COSM1440517	p.Asp347Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949274T>C	NCI-TCGA Cosmic
COSM1073348	p.Met348Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.131949272T>C	NCI-TCGA Cosmic
rs1383990931	p.Ter350Gly	stop lost	-	NC_000006.12:g.131949266A>C	TOPMed

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;CTD_human;LHGDN
C0001815	Primary Myelofibrosis	disease	BEFREE
C0002395	Alzheimer's Disease	disease	BEFREE;LHGDN
C0002793	Anaplasia	disease	BEFREE
C0003130	Anoxia	phenotype	LHGDN
C0003496	Aortic Rupture	disease	BEFREE
C0003504	Aortic Valve Insufficiency	disease	BEFREE;CTD_human;RGD
C0003850	Arteriosclerosis	disease	BEFREE
C0003862	Arthralgia	phenotype	HPO
C0003864	Arthritis	disease	BEFREE;HPO
C0003873	Rheumatoid Arthritis	disease	BEFREE;CTD_human
C0004096	Asthma	disease	BEFREE
C0004153	Atherosclerosis	disease	BEFREE
C0004238	Atrial Fibrillation	disease	BEFREE
C0004364	Autoimmune Diseases	group	HPO
C0004368	Autoimmune state	phenotype	HPO
C0004623	Bacterial Infections	group	BEFREE
C0005398	Cholestasis, Extrahepatic	disease	CTD_human
C0005411	Biliary Atresia	disease	LHGDN
C0005940	Bone Diseases	group	BEFREE;RGD
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0006287	Bronchopulmonary Dysplasia	disease	BEFREE
C0007095	Carcinoid Tumor	group	LHGDN
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE;LHGDN
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007196	Restrictive cardiomyopathy	disease	RGD
C0007286	Carpal Tunnel Syndrome	disease	BEFREE
C0007570	Celiac Disease	disease	BEFREE
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008312	Primary biliary cirrhosis	disease	RGD
C0008354	Cholera	disease	BEFREE
C0008479	Chondrosarcoma	disease	BEFREE
C0008487	Chordoma	disease	BEFREE
C0009324	Ulcerative Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009714	Hepatic Fibrosis, Congenital	disease	BEFREE
C0009917	Contracture	group	HPO
C0009918	Contracture of joint	phenotype	HPO
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0010346	Crohn Disease	disease	BEFREE
C0011168	Deglutition Disorders	group	HPO
C0011334	Dental caries	disease	HPO
C0011616	Contact Dermatitis	disease	CTD_human
C0011644	Scleroderma	disease	BEFREE
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0011854	Diabetes Mellitus, Insulin-Dependent	disease	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE;RGD
C0011881	Diabetic Nephropathy	disease	BEFREE;LHGDN
C0011884	Diabetic Retinopathy	disease	LHGDN;RGD
C0013404	Dyspnea	phenotype	HPO
C0014175	Endometriosis	disease	BEFREE
C0014859	Esophageal Neoplasms	group	BEFREE
C0015302	External exotoses	disease	BEFREE
C0016059	Fibrosis	phenotype	LHGDN
C0016978	gallbladder neoplasm	disease	LHGDN
C0017168	Gastroesophageal reflux disease	disease	HPO
C0017601	Glaucoma	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;LHGDN
C0017661	IGA Glomerulonephritis	disease	LHGDN
C0017662	Glomerulonephritis, Membranoproliferative	disease	RGD
C0017668	Focal glomerulosclerosis	disease	BEFREE;CTD_human
C0018553	Hamartoma Syndrome, Multiple	disease	BEFREE
C0018799	Heart Diseases	group	BEFREE
C0018801	Heart failure	disease	BEFREE;CTD_human
C0018802	Congestive heart failure	disease	BEFREE;CTD_human
C0018834	Heartburn	phenotype	HPO
C0019158	Hepatitis	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE
C0019196	Hepatitis C	disease	BEFREE
C0020456	Hyperglycemia	disease	BEFREE
C0020538	Hypertensive disease	group	BEFREE;CTD_human
C0020541	Hypertension, Portal	disease	BEFREE;LHGDN
C0020542	Pulmonary Hypertension	phenotype	LHGDN;RGD
C0021294	Infant, Premature	phenotype	BEFREE
C0021361	Female infertility	phenotype	CTD_human
C0021367	Mammary Ductal Carcinoma	disease	BEFREE
C0021390	Inflammatory Bowel Diseases	group	BEFREE
C0021831	Intestinal Diseases	group	BEFREE
C0022548	Keloid	phenotype	BEFREE
C0022658	Kidney Diseases	group	BEFREE
C0022661	Kidney Failure, Chronic	disease	LHGDN
C0023212	Left-Sided Heart Failure	disease	CTD_human
C0023267	Fibroid Tumor	group	BEFREE;LHGDN
C0023418	leukemia	disease	BEFREE
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023485	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	disease	BEFREE;CTD_human
C0023652	Lichen Sclerosus et Atrophicus	disease	BEFREE
C0023890	Liver Cirrhosis	disease	BEFREE;CTD_human
C0023892	Biliary cirrhosis	disease	RGD
C0023893	Liver Cirrhosis, Experimental	disease	CTD_human
C0023895	Liver diseases	group	BEFREE
C0023896	Alcoholic Liver Diseases	group	BEFREE
C0023903	Liver neoplasms	group	BEFREE
C0024115	Lung diseases	group	CTD_human
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE;RGD
C0024121	Lung Neoplasms	group	CTD_human
C0024299	Lymphoma	group	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE
C0025500	Mesothelioma	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE
C0026847	Spinal Muscular Atrophy	disease	BEFREE
C0026850	Muscular Dystrophy	disease	LHGDN
C0026896	Myasthenia Gravis	disease	BEFREE
C0027051	Myocardial Infarction	disease	BEFREE;RGD
C0027498	Nausea and vomiting	phenotype	HPO
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0027686	Pathologic Neovascularization	phenotype	LHGDN
C0027697	Nephritis	disease	BEFREE
C0027708	Nephroblastoma	disease	BEFREE
C0027832	Neurofibromatosis 2	disease	BEFREE
C0028754	Obesity	disease	BEFREE
C0028961	Oliguria	disease	HPO
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE;LHGDN
C0029866	Other ureteric obstruction	phenotype	RGD
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	BEFREE;LHGDN
C0030305	Pancreatitis	disease	BEFREE
C0030567	Parkinson Disease	disease	RGD
C0031154	Peritonitis	disease	BEFREE
C0033054	Prenatal Exposure Delayed Effects	disease	CTD_human
C0034065	Pulmonary Embolism	disease	RGD
C0034069	Pulmonary Fibrosis	disease	BEFREE;CTD_human;HPO;RGD
C0035078	Kidney Failure	disease	BEFREE
C0035220	Respiratory Distress Syndrome, Newborn	disease	BEFREE
C0035222	Respiratory Distress Syndrome, Adult	disease	BEFREE
C0035305	Retinal Detachment	disease	BEFREE
C0035309	Retinal Diseases	group	BEFREE
C0036205	Sarcoidosis, Pulmonary	disease	BEFREE
C0036420	Localized scleroderma	disease	BEFREE
C0036421	Systemic Scleroderma	disease	BEFREE;CTD_human;LHGDN
C0036690	Septicemia	disease	BEFREE
C0037052	Sick Sinus Syndrome	disease	BEFREE
C0037299	Skin Ulcer	phenotype	HPO
C0037579	Soft Tissue Neoplasms	group	BEFREE
C0038160	Staphylococcal Infections	group	BEFREE
C0038279	Sterility, Postpartum	phenotype	CTD_human
C0038356	Stomach Neoplasms	group	LHGDN
C0039503	Tendinitis	disease	RGD
C0041956	Ureteral obstruction	phenotype	BEFREE
C0042133	Uterine Fibroids	group	BEFREE
C0042769	Virus Diseases	group	BEFREE
C0043352	Xerostomia	disease	HPO
C0085786	Hamman-Rich syndrome	disease	BEFREE;CTD_human
C0086432	Hyalinosis, Segmental Glomerular	disease	CTD_human
C0086543	Cataract	disease	BEFREE
C0149721	Left Ventricular Hypertrophy	disease	BEFREE
C0151517	Complete atrioventricular block	disease	BEFREE
C0151650	Renal fibrosis	disease	BEFREE
C0151744	Myocardial Ischemia	disease	BEFREE
C0151786	Muscle Weakness	phenotype	HPO
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0152451	Chronic glomerulonephritis	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153452	Malignant neoplasm of gallbladder	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0153690	Secondary malignant neoplasm of bone	disease	BEFREE
C0155568	Rheumatic aortic regurgitation	disease	RGD
C0156147	Crohn's disease of large bowel	disease	BEFREE
C0156181	Peritoneal adhesion	phenotype	BEFREE
C0158266	Intervertebral Disc Degeneration	disease	BEFREE
C0162351	Contact hypersensitivity	phenotype	CTD_human
C0162810	Cicatrix, Hypertrophic	phenotype	BEFREE
C0178664	Glomerulosclerosis (disorder)	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0205641	Adenocarcinoma, Basal Cell	disease	CTD_human
C0205642	Adenocarcinoma, Oxyphilic	disease	CTD_human
C0205643	Carcinoma, Cribriform	disease	CTD_human
C0205644	Carcinoma, Granular Cell	disease	CTD_human
C0205645	Adenocarcinoma, Tubular	disease	CTD_human
C0206062	Lung Diseases, Interstitial	group	BEFREE
C0206138	CREST Syndrome	disease	ORPHANET
C0206368	Exfoliation Syndrome	disease	BEFREE
C0206754	Neuroendocrine Tumors	group	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0220756	Niemann-Pick Disease, Type C	disease	BEFREE
C0221204	Lytic lesion	phenotype	HPO
C0221271	Elastosis perforans serpiginosa	disease	BEFREE
C0235527	Heart Failure, Right-Sided	disease	CTD_human
C0235618	Proliferative glomerulonephritis	disease	BEFREE
C0235782	Gallbladder Carcinoma	disease	BEFREE
C0235833	Congenital diaphragmatic hernia	disease	CTD_human
C0235896	Pulmonary Infiltrate	phenotype	HPO
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238067	Colitis, Collagenous	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE;CTD_human
C0242073	Pulmonary congestion	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE;CTD_human
C0242852	Proliferative vitreoretinopathy	disease	BEFREE
C0243026	Sepsis	disease	BEFREE
C0263009	Sclerosis of the skin	disease	BEFREE
C0264774	Mitral and aortic incompetence	disease	RGD
C0265699	Congenital hernia of foramen of Morgagni	disease	CTD_human
C0265700	Congenital hernia of foramen of Bochdalek	disease	CTD_human
C0267941	Pancreatitis, Acute Necrotizing	disease	BEFREE
C0268009	Hyperosmolality	disease	BEFREE
C0268732	Nephritic syndrome	disease	BEFREE
C0276623	Chronic viral hepatitis	disease	BEFREE
C0278883	Metastatic melanoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0333068	Flexion contracture	phenotype	HPO
C0334579	Anaplastic astrocytoma	disease	BEFREE
C0339143	Thyroid associated opthalmopathies	disease	BEFREE
C0339573	Glaucoma, Primary Open Angle	disease	BEFREE
C0340643	Dissection of aorta	disease	BEFREE
C0341439	Chronic liver disease	group	BEFREE
C0341869	Subfertility, Female	disease	CTD_human
C0345967	Malignant mesothelioma	disease	BEFREE
C0346040	Stage 0 Skin Melanoma	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0392400	Diffuse malignant mesothelioma	disease	BEFREE
C0399440	Hereditary gingival fibromatosis	disease	BEFREE
C0400822	Colitis, Lymphocytic	disease	BEFREE
C0403416	Idiopathic crescentic glomerulonephritis	disease	BEFREE
C0403592	Chronic rejection of renal transplant	disease	BEFREE
C0431109	Choroid Plexus Carcinoma	disease	BEFREE
C0521607	Peritoneal Fibrosis	disease	BEFREE
C0521707	Bilateral cataracts (disorder)	disease	BEFREE
C0524909	Hepatitis B, Chronic	disease	BEFREE;CTD_human
C0524910	Hepatitis C, Chronic	disease	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553980	Endomyocardial Fibrosis	phenotype	RGD
C0555198	Malignant Glioma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0746102	Chronic lung disease	group	BEFREE
C0748540	Scleroderma, Limited	disease	ORPHANET
C0751606	Adult Acute Lymphocytic Leukemia	disease	BEFREE
C0852283	Respiratory Distress Syndrome	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0879615	Stromal Neoplasm	disease	BEFREE
C0917730	Female sterility	phenotype	CTD_human
C0919267	ovarian neoplasm	disease	BEFREE;LHGDN
C0947751	Vascular inflammations	phenotype	BEFREE
C1135196	Heart Failure, Diastolic	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1258104	Diffuse Scleroderma	disease	BEFREE;ORPHANET
C1274865	Scleroderma-like secondary cutaneous sclerosis	disease	BEFREE
C1292769	Precursor B-cell lymphoblastic leukemia	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1332986	Childhood Osteosarcoma	disease	BEFREE
C1333177	Lymphoproliferative Disorder of the Skin	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1378703	Renal carcinoma	disease	BEFREE
C1384606	Dyspareunia	phenotype	HPO
C1397307	Cardiac fibrosis	disease	BEFREE
C1449563	Cardiomyopathy, Familial Idiopathic	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1511789	Desmoplastic	disease	BEFREE
C1512981	Mammary Tumorigenesis	phenotype	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1561643	Chronic Kidney Diseases	group	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C1800706	Idiopathic Pulmonary Fibrosis	disease	BEFREE
C1836735	hypopigmented skin patch	phenotype	HPO
C1850530	Flexion contractures of joints	phenotype	HPO
C1868684	EAR, PATELLA, SHORT STATURE SYNDROME	disease	BEFREE
C1956089	Osteophyte	disease	BEFREE
C1959583	Myocardial Failure	disease	CTD_human
C1960048	Severe persistent asthma	disease	BEFREE
C1961102	Precursor Cell Lymphoblastic Leukemia Lymphoma	disease	BEFREE
C1961112	Heart Decompensation	phenotype	CTD_human
C2239176	Liver carcinoma	disease	BEFREE;LHGDN
C2350236	Idiopathic Interstitial Pneumonias	disease	BEFREE
C2717860	Encapsulating Peritoneal Sclerosis	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C3159311	BORNHOLM EYE DISEASE	disease	BEFREE
C3160718	PARKINSON DISEASE, LATE-ONSET	disease	BEFREE
C3714745	Malabsorption	phenotype	HPO
C3714756	Intellectual Disability	group	GENOMICS_ENGLAND
C3811653	Experimental Organism Basal Cell Carcinoma	phenotype	BEFREE
C3839507	Diminished ovarian reserve	disease	BEFREE
C3887486	Interstitial lung fibrosis	phenotype	BEFREE
C4021910	Narrow foramen obturatorium	phenotype	HPO
C4022018	Telangiectasia of the skin	phenotype	HPO
C4022020	Mucosal telangiectasiae	phenotype	HPO
C4048328	cervical cancer	disease	BEFREE
C4280623	Rotting teeth	phenotype	HPO
C4317146	Acid reflux	phenotype	HPO

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0001968	fibronectin binding	IEA
GO:0005178	integrin binding	IBA
GO:0005515	protein binding	IPI
GO:0005520	insulin-like growth factor binding	IEA
GO:0008022	protein C-terminus binding	IPI
GO:0008083	growth factor activity	IEA
GO:0008201	heparin binding	IBA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0001502	cartilage condensation	IEA
GO:0001503	ossification	IEA
GO:0001525	angiogenesis	IEA
GO:0001894	tissue homeostasis	IEA
GO:0006367	transcription initiation from RNA polymerase II promoter	TAS
GO:0007155	cell adhesion	IBA
GO:0007160	cell-matrix adhesion	IEA
GO:0007165	signal transduction	IBA
GO:0007229	integrin-mediated signaling pathway	IEA
GO:0007568	aging	IEA
GO:0008284	positive regulation of cell population proliferation	IEA
GO:0008543	fibroblast growth factor receptor signaling pathway	IEA
GO:0008544	epidermis development	TAS
GO:0009611	response to wounding	TAS
GO:0009749	response to glucose	IEA
GO:0010628	positive regulation of gene expression	IEA
GO:0010629	negative regulation of gene expression	IEA
GO:0016477	cell migration	IEA
GO:0030154	cell differentiation	IEA
GO:0030324	lung development	IEA
GO:0032330	regulation of chondrocyte differentiation	IEA
GO:0032355	response to estradiol	IEA
GO:0032967	positive regulation of collagen biosynthetic process	IEA
GO:0034059	response to anoxia	IEA
GO:0035556	intracellular signal transduction	IEA
GO:0035988	chondrocyte proliferation	IEA
GO:0043200	response to amino acid	IEA
GO:0043280	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	IEA
GO:0043434	response to peptide hormone	IEA
GO:0045597	positive regulation of cell differentiation	IDA
GO:0046330	positive regulation of JNK cascade	IDA
GO:0050867	positive regulation of cell activation	IEA
GO:0051385	response to mineralocorticoid	IEA
GO:0051496	positive regulation of stress fiber assembly	IDA
GO:0060401	cytosolic calcium ion transport	IEA
GO:0060452	positive regulation of cardiac muscle contraction	IEA
GO:0060548	negative regulation of cell death	IBA
GO:0070278	extracellular matrix constituent secretion	IEA
GO:0070318	positive regulation of G0 to G1 transition	IEA
GO:0070374	positive regulation of ERK1 and ERK2 cascade	IDA
GO:0070542	response to fatty acid	IEA
GO:0071897	DNA biosynthetic process	IEA
GO:0072593	reactive oxygen species metabolic process	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IEA
GO:0005801	cis-Golgi network	IEA
GO:0005829	cytosol	IEA
GO:0005886	plasma membrane	TAS
GO:0005938	cell cortex	IEA
GO:0031012	extracellular matrix	IBA
GO:0048471	perinuclear region of cytoplasm	IEA
GO:0062023	collagen-containing extracellular matrix	HDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8878159	Transcriptional regulation by RUNX3	TAS
R-HSA-8951671	RUNX3 regulates YAP1-mediated transcription	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C432747	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC results in decreased expression of CCN2 mRNA	15313899
C026486	1,2,5,6-dibenzanthracene	1,2,5,6-dibenzanthracene results in increased expression of CCN2 mRNA	26377693
C031763	1,3-butadiene	1,3-butadiene results in increased expression of CCN2 mRNA	29038090
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Diethylnitrosamine] results in increased expression of CCN2 mRNA	21391223
C097240	15-deoxy-delta(12,14)-prostaglandin J2	15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]	19429239
C097240	15-deoxy-delta(12,14)-prostaglandin J2	15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	19429239
C097240	15-deoxy-delta(12,14)-prostaglandin J2	SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]	19429239
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of CCN2 mRNA	24810058
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of CCN2 mRNA	25380136
C032668	1-nitropyrene	1-nitropyrene results in increased expression of CCN2 mRNA	19041380
C548651	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of CCN2 mRNA	19933214
C101670	2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate	2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [kallidin, des-Arg(10)- results in increased expression of CCN2 mRNA]	15703175
C101670	2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate	2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	15703175
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	26054450
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of CCN2 mRNA	17965732
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of CCN2 protein	17965732
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the expression of CCN2 mRNA	19414516
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA]	19414516
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of CCN2 mRNA]	19414516
C038890	2,3,4,7,8-pentachlorodibenzofuran	2,3,4,7,8-pentachlorodibenzofuran results in decreased expression of CCN2 mRNA	21724226
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran affects the expression of CCN2 mRNA	20702594
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran results in decreased expression of CCN2 mRNA	21724226
C013186	2,3-pentanedione	2,3-pentanedione results in increased expression of CCN2 mRNA	25710175
C064515	2',4'-dichlorobenzamil amiloride	2',4'-dichlorobenzamil amiloride inhibits the reaction [kallidin, des-Arg(10)- results in increased expression of CCN2 mRNA]	15703175
C064515	2',4'-dichlorobenzamil amiloride	2',4'-dichlorobenzamil amiloride inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	15703175
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	26054450
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of CCN2 mRNA	15940639
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of CCN2 protein	15940639
D015073	2-Acetylaminofluorene	Iloprost inhibits the reaction [2-Acetylaminofluorene results in increased expression of CCN2 mRNA]	15940639
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in increased expression of CCN2 mRNA	29704546
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCN2 mRNA]	23196670
C560356	(2S,4R)-methyl-1-acetyl-4-(N-(4-bromophenyl)sulfamoyloxy)pyrrolidine-2-carboxylate	(2S,4R)-methyl-1-acetyl-4-(N-(4-bromophenyl)sulfamoyloxy)pyrrolidine-2-carboxylate results in decreased expression of CCN2 protein	21349324
C018855	2-tert-butylhydroquinone	2-tert-butylhydroquinone results in decreased expression of CCN2 mRNA	16014739
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl affects the expression of CCN2 mRNA	20702594
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCN2 mRNA	23196670
C014464	3,4-dichloroaniline	3,4-dichloroaniline results in decreased expression of CCN2 mRNA	24172598
C017906	3-dinitrobenzene	3-dinitrobenzene results in increased expression of CCN2 mRNA	24140754
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane results in increased expression of CCN2 mRNA	25380136
C583074	4,4'-hexafluorisopropylidene diphenol	4,4'-hexafluorisopropylidene diphenol results in increased expression of CCN2 mRNA	25912373
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of CCN2 mRNA	20018196
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCN2 mRNA	19480007
D000079	Acetaldehyde	Acetaldehyde results in increased expression of CCN2 mRNA	19280452
D000079	Acetaldehyde	CCN2 protein results in increased abundance of Acetaldehyde	19280452
D000079	Acetaldehyde	[Ethanol results in increased expression of CCN2 protein] which results in increased abundance of Acetaldehyde	19280452
D000082	Acetaminophen	Acetaminophen affects the expression of CCN2 mRNA	25458485
D000082	Acetaminophen	Acetaminophen results in decreased expression of CCN2 mRNA	22230336
D000082	Acetaminophen	Acetaminophen results in increased expression of CCN2 mRNA	21420995
D000082	Acetaminophen	Acetaminophen affects the expression of CCN2 mRNA	15606129; 17562736;
D000082	Acetaminophen	Acetaminophen results in increased expression of CCN2 mRNA	11264010; 12392966; 14550746;
D000082	Acetaminophen	NOS2 protein inhibits the reaction [Acetaminophen results in increased expression of CCN2 mRNA]	12392966
D000082	Acetaminophen	TNFRSF1A protein affects the reaction [Acetaminophen results in increased expression of CCN2 mRNA]	14550746
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	17270171
C109238	acyline	acyline results in decreased expression of CCN2 mRNA	17510436
D000336	Aerosols	Aerosols affects the expression of CCN2 mRNA	29505817
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of CCN2 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of CCN2 mRNA	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of CCN2 mRNA	19770486
D016607	Aflatoxin M1	Aflatoxin M1 results in decreased expression of CCN2 mRNA	30928695
D000450	Aldosterone	Aldosterone results in increased expression of CCN2 protein	17278980
D000450	Aldosterone	Spironolactone inhibits the reaction [Aldosterone results in increased expression of CCN2 protein]	17278980
C038491	allyl sulfide	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
C038491	allyl sulfide	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D000509	alpha-Fetoproteins	alpha-Fetoproteins inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CCN2 mRNA]	15994428
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of CCN2 mRNA	16483693
C030419	andrographolide	[andrographolide co-treated with beta-Naphthoflavone] results in decreased expression of CCN2 mRNA	19737545
D000872	Anthocyanins	Anthocyanins results in decreased expression of CCN2 mRNA	30056145
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of CCN2 mRNA	24449571
C000228	aristolochic acid I	aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein]	24412304
D034341	Aristolochic Acids	Aristolochic Acids results in increased expression of CCN2 mRNA	19717638
D001151	Arsenic	Arsenic affects the expression of CCN2 protein	24675094
D001151	Arsenic	Arsenic results in increased expression of CCN2 mRNA	23942117
D001151	Arsenic	Arsenic results in increased expression of CCN2 mRNA	24348802
D001151	Arsenic	Grape Seed Extract inhibits the reaction [Arsenic results in increased expression of CCN2 mRNA]	24348802
D000077237	Arsenic Trioxide	Arsenic Trioxide inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	24762191
D001194	Asbestos	Asbestos results in decreased expression of CCN2 mRNA	22076105
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of CCN2 mRNA	18687144
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in increased expression of CCN2	19817698
D017632	Asbestos, Serpentine	TGFB1 protein affects the reaction [Asbestos, Serpentine results in increased expression of CCN2]	19817698
C011669	ascorbate-2-phosphate	ascorbate-2-phosphate results in decreased expression of CCN2 mRNA	17306970
D001241	Aspirin	Aspirin inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]	14586741
D001241	Aspirin	Aspirin inhibits the reaction [Streptozocin results in increased expression of CCN2 mRNA]	14586741
D001280	Atrazine	Atrazine results in increased expression of CCN2 mRNA	25616260
D001280	Atrazine	Atrazine results in increased expression of CCN2 protein	25616260
D001280	Atrazine	ESR1 protein promotes the reaction [Atrazine results in increased expression of CCN2 protein]	25616260
D001280	Atrazine	GPER1 protein promotes the reaction [Atrazine results in increased expression of CCN2 protein]	25616260
C447119	bazedoxifene	bazedoxifene results in increased expression of CCN2 mRNA	19914376
C487081	belinostat	belinostat results in increased expression of CCN2 mRNA	19606018; 23671600;
C044946	benazepril	benazepril results in decreased expression of CCN2 mRNA	17121042
D001548	Benzalkonium Compounds	Benzalkonium Compounds results in decreased expression of CCN2 mRNA	25377654
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CCN2 mRNA	20106945; 21632981;
D001564	Benzo(a)pyrene	AHR protein promotes the reaction [Benzo(a)pyrene results in decreased expression of CCN2 mRNA]	15034205
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CCN2 mRNA	15034205; 19770486;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of CCN2 mRNA	21569818; 22228805; 22610609;
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in decreased expression of CCN2 mRNA	19737606
D019324	beta-Naphthoflavone	[andrographolide co-treated with beta-Naphthoflavone] results in decreased expression of CCN2 mRNA	19737545
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in increased expression of CCN2 mRNA	15240111
D019324	beta-Naphthoflavone	[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCN2 mRNA	18164116
C020228	betanin	betanin inhibits the reaction [Fructose results in increased expression of CCN2 protein]	25559852
D001629	Bezafibrate	Bezafibrate inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	19429239
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of CCN2 mRNA	25912373
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]	10026205
C006780	bisphenol A	bisphenol A affects the expression of CCN2 mRNA	20170705
C006780	bisphenol A	bisphenol A promotes the reaction [CCN2 protein binds to ESR1 protein]	27156127
C006780	bisphenol A	bisphenol A results in decreased expression of CCN2 mRNA	27685785; 29275510; 29718440;
C006780	bisphenol A	bisphenol A results in increased expression of CCN2 mRNA	22552965
C006780	bisphenol A	bisphenol A results in increased expression of CCN2 protein	22552965
C006780	bisphenol A	GPER1 mRNA affects the reaction [bisphenol A results in increased expression of CCN2 protein]	22552965
C006780	bisphenol A	bisphenol A results in increased expression of CCN2 mRNA	24586524
C006780	bisphenol A	bisphenol A affects the expression of CCN2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in decreased expression of CCN2 protein	24552547
D001761	Bleomycin	Bleomycin results in increased expression of CCN2 mRNA	19080365; 26817844;
D001761	Bleomycin	Bleomycin results in increased expression of CCN2 protein	19080365
D001761	Bleomycin	[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D001761	Bleomycin	[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D001761	Bleomycin	[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D001761	Bleomycin	Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]	19080365
D001761	Bleomycin	Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein]	19080365
D003994	Bucladesine	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA	20823114
C584509	C646 compound	C646 compound results in decreased expression of CCN2 mRNA	26191083
D002104	Cadmium	Cadmium inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D002104	Cadmium	[[Cadmium Chloride results in increased abundance of Cadmium] which co-treated with Dietary Fats] results in increased expression of CCN2 mRNA	30912652
D002104	Cadmium	Cadmium results in increased expression of CCN2 mRNA	15240111
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of CCN2 mRNA	26314618
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of CCN2 mRNA	26472689
D019256	Cadmium Chloride	[[Cadmium Chloride results in increased abundance of Cadmium] which co-treated with Dietary Fats] results in increased expression of CCN2 mRNA	30912652
D019256	Cadmium Chloride	MT3 affects the reaction [Cadmium Chloride affects the expression of CCN2 mRNA]	20371981
D019256	Cadmium Chloride	Cadmium Chloride affects the expression of CCN2 mRNA	22110744
C081643	candesartan	candesartan results in decreased expression of CCN2 mRNA	16685210
C077793	candesartan cilexetil	candesartan cilexetil inhibits the reaction [sodium arsenite results in increased expression of CCN2 protein]	27889505
D002220	Carbamazepine	Carbamazepine affects the expression of CCN2 mRNA	25979313
D002251	Carbon Tetrachloride	ADIPOQ protein affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	14724832
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CCN2 mRNA	14724832; 27042213; 27339419;
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CCN2 protein	17565644; 17657819;
D002251	Carbon Tetrachloride	HAS3 protein affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	27042213
D002251	Carbon Tetrachloride	rofecoxib inhibits the reaction [Carbon Tetrachloride results in increased expression of CCN2 protein]	17565644
D002251	Carbon Tetrachloride	SMAD7 protein inhibits the reaction [Carbon Tetrachloride results in increased expression of CCN2 protein]	17657819
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CCN2 mRNA	16484506; 16652398; 22989100;
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CCN2 protein	16420518; 16652398;
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased activity of TGFB1 protein]	16652398
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]	16652398
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	16652398
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 protein]	16652398
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]	16652398
D002251	Carbon Tetrachloride	CCN2 affects the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]	16652398
D002251	Carbon Tetrachloride	Pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	16484506
D002251	Carbon Tetrachloride	Quercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	22989100
C010063	carbonyl sulfide	carbonyl sulfide results in increased expression of CCN2 mRNA	19395590
D002331	Carnitine	Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]	26581635
D002392	Catechin	[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of CCN2 mRNA	24763279
D002509	Cephaloridine	Cephaloridine results in decreased expression of CCN2 mRNA	18500788
C100187	chloropicrin	chloropicrin results in increased expression of CCN2 mRNA	26352163
D002737	Chloroprene	Chloroprene results in increased expression of CCN2 mRNA	23125180
D004390	Chlorpyrifos	Chlorpyrifos affects the expression of CCN2 mRNA	21496282
D002762	Cholecalciferol	Cholecalciferol results in decreased expression of CCN2 mRNA	16508948
D002762	Cholecalciferol	Cholecalciferol results in increased expression of CCN2 mRNA	17170073
D002793	Cholic Acids	[Cyclosporine co-treated with Cholic Acids] affects the expression of CCN2 mRNA	27344345
D002794	Choline	CCL2 protein inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]	20697377
D002794	Choline	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA	18991162
D002794	Choline	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein	18991162
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of CCN2	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CCN2 gene	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CCN2 mRNA	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA	20697377; 22915297;
D002794	Choline	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]	22915297
D002794	Choline	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA]	18991162
D002794	Choline	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein]	18991162
C012843	cinnamic aldehyde	cinnamic aldehyde results in decreased expression of CCN2 mRNA	17178418
D002945	Cisplatin	Cisplatin affects the expression of CCN2 mRNA	23300844
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of CCN2 mRNA	27392435
D002945	Cisplatin	[Cisplatin co-treated with Paclitaxel] affects the expression of CCN2 mRNA	20705681
D002945	Cisplatin	Cisplatin results in decreased expression of CCN2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of CCN2 mRNA	21151649
D002990	Clobetasol	Clobetasol results in increased expression of CCN2 mRNA	27462272
D003035	Cobalt	Cobalt results in decreased expression of CCN2 mRNA	17967803
C018021	cobaltous chloride	cobaltous chloride promotes the reaction [HIF1A protein results in increased expression of CCN2 mRNA]	17034590
C018021	cobaltous chloride	cobaltous chloride promotes the reaction [HIF1A protein results in increased expression of CCN2 protein]	17034590
C018021	cobaltous chloride	cobaltous chloride promotes the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	17034590
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of CCN2 mRNA	19320972
C018021	cobaltous chloride	cobaltous chloride results in increased expression of CCN2 mRNA	17034590; 19376846;
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of CCN2 mRNA	24386269
D003042	Cocaine	Cocaine results in decreased expression of CCN2 mRNA	18000554
D003042	Cocaine	Cocaine results in decreased expression of CCN2 protein	18000554
C024989	coenzyme Q10	coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CCN2 protein]	27087047
D003069	Coffee	Coffee inhibits the reaction [Thioacetamide results in increased expression of CCN2 protein]	22899499
D003300	Copper	[NSC 689534 binds to Copper] which results in increased expression of CCN2 mRNA	20971185
D019327	Copper Sulfate	Copper Sulfate affects the expression of CCN2 mRNA	19549813
D003474	Curcumin	Curcumin results in decreased expression of CCN2 mRNA	17965732
D003474	Curcumin	Curcumin results in decreased expression of CCN2 protein	19764552
D003474	Curcumin	IKBKB protein inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]	17965732
D003474	Curcumin	Lipopolysaccharides inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]	17965732
D003474	Curcumin	NFKBIA protein inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]	17965732
D003474	Curcumin	PPARG protein promotes the reaction [Curcumin results in decreased expression of CCN2 mRNA]	17965732
D003474	Curcumin	Curcumin results in decreased expression of CCN2 protein	17965732
D003474	Curcumin	Curcumin results in decreased expression of CCN2	18462866
D000242	Cyclic AMP	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA]	19414516
D003513	Cycloheximide	Cycloheximide results in increased expression of CCN2 mRNA	19684285
D003513	Cycloheximide	[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA	19684285
D016572	Cyclosporine	Cyclosporine affects the expression of CCN2 mRNA	20106945
D016572	Cyclosporine	[Cyclosporine co-treated with Cholic Acids] affects the expression of CCN2 mRNA	27344345
D016572	Cyclosporine	Cyclosporine results in decreased expression of CCN2 mRNA	25562108; 27989131;
D016572	Cyclosporine	Cyclosporine results in increased expression of CCN2 mRNA	21632981
D016572	Cyclosporine	Cyclosporine results in increased expression of and results in increased secretion of CCN2 protein	21354196
D016572	Cyclosporine	Cyclosporine results in increased expression of CCN2 mRNA	21354196
D016572	Cyclosporine	Cyclosporine affects the expression of CCN2 mRNA	24971338
D016572	Cyclosporine	Cyclosporine affects the expression of CCN2 protein	24971338
D016572	Cyclosporine	Cyclosporine results in decreased expression of CCN2 mRNA	21865292
D000077209	Decitabine	Decitabine affects the expression of CCN2 mRNA	23300844
D000077209	Decitabine	Decitabine results in increased expression of CCN2 mRNA	21856257
D000077209	Decitabine	Decitabine results in decreased expression of CCN2 mRNA	27915011
D003907	Dexamethasone	Dexamethasone results in increased expression of CCN2 mRNA	22733784
C041517	dibenzo(a,l)pyrene	dibenzo(a,l)pyrene results in increased expression of CCN2 mRNA	15735009
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of CCN2 mRNA	17361019; 21266533;
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of CCN2 mRNA	21266533
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in decreased expression of CCN2 mRNA	28962523
C000944	dicrotophos	dicrotophos results in increased expression of CCN2 mRNA	28302478
D004041	Dietary Fats	[[Cadmium Chloride results in increased abundance of Cadmium] which co-treated with Dietary Fats] results in increased expression of CCN2 mRNA	30912652
D004041	Dietary Fats	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA	18991162
D004041	Dietary Fats	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein	18991162
D004041	Dietary Fats	Dietary Fats results in decreased expression of CCN2 mRNA	28673684
D004041	Dietary Fats	Dietary Fats results in increased expression of CCN2 mRNA	18042831; 22609946;
D004041	Dietary Fats	Dietary Fats results in increased expression of CCN2 protein	23821548; 27370414;
D004041	Dietary Fats	RALBP1 affects the reaction [Dietary Fats results in increased expression of CCN2 protein]	23821548
D004041	Dietary Fats	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA]	18991162
D004041	Dietary Fats	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein]	18991162
D004041	Dietary Fats	[Streptozocin co-treated with Dietary Fats] results in increased expression of CCN2 protein	24707343
D004041	Dietary Fats	sulforafan inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of CCN2 protein]	24707343
D004041	Dietary Fats	Zinc inhibits the reaction [Dietary Fats results in increased expression of CCN2 protein]	27370414
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of CCN2 protein	29669060
D004052	Diethylnitrosamine	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Diethylnitrosamine] results in increased expression of CCN2 mRNA	21391223
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCN2 mRNA	18164116
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of CCN2 mRNA	19638242
D004128	Dimethylnitrosamine	CCN2 protein affects the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]	17344905
D004128	Dimethylnitrosamine	CCN2 protein affects the reaction [Dimethylnitrosamine results in increased expression of TGFB1 protein]	17344905
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of CCN2 mRNA	15067225; 17344905; 25380136;
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of CCN2 protein	17344905
D015232	Dinoprostone	[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D015232	Dinoprostone	[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D015232	Dinoprostone	[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]	28434932
D004237	Diuron	Diuron metabolite results in decreased expression of CCN2 mRNA	24172598
D004237	Diuron	Diuron results in increased expression of CCN2 mRNA	21551480
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
D004317	Doxorubicin	Doxorubicin affects the expression of CCN2 mRNA	15205334
D004317	Doxorubicin	Doxorubicin results in increased expression of CCN2 mRNA	16579640; 28940058; 29803840; 30031762;
D004317	Doxorubicin	Doxorubicin affects the expression of CCN2 mRNA	15033991
D004317	Doxorubicin	Doxorubicin results in increased expression of CCN2 mRNA	22712078; 28710503;
D004317	Doxorubicin	Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]	22712078; 28710503;
D004317	Doxorubicin	NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]	28710503
D004317	Doxorubicin	coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CCN2 protein]	27087047
D004317	Doxorubicin	Doxorubicin results in increased expression of CCN2 protein	27087047
D013759	Dronabinol	Dronabinol results in decreased expression of CCN2 mRNA	17578508
D004391	Dust	Dust results in increased expression of CCN2 mRNA	15735009
C479799	(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide	(E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide results in increased expression of CCN2 mRNA	15528975
C070609	EMD 53998	EMD 53998 analog results in increased expression of CCN2 mRNA	24977338
D004656	Enalapril	Enalapril results in decreased expression of CCN2 mRNA	25037058
D004656	Enalapril	Enalapril inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	21416479
D004656	Enalapril	Enalapril results in decreased expression of CCN2 mRNA	19349682
D004656	Enalapril	Enalapril results in decreased expression of CCN2 protein	18812665; 19349682;
D004726	Endosulfan	Endosulfan affects the expression of CCN2 mRNA	29391264
C045651	epigallocatechin gallate	epigallocatechin gallate affects the expression of CCN2	25955525
D004837	Epinephrine	Epinephrine results in increased expression of CCN2 mRNA	19300450
D015251	Epirubicin	Epirubicin results in increased expression of CCN2 mRNA	22712078
D015251	Epirubicin	Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]	22712078
D004918	Erythromycin Estolate	Erythromycin Estolate results in decreased expression of CCN2 mRNA	24412560
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in increased expression of CCN2 protein]	25616260
D004958	Estradiol	Estradiol affects the expression of CCN2 mRNA	14699072; 25321415;
D004958	Estradiol	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA	20823114
D004958	Estradiol	Estradiol results in increased expression of CCN2 mRNA	19153601; 25616260;
D004958	Estradiol	Estradiol results in increased expression of CCN2 protein	25616260
D004958	Estradiol	GPER1 protein promotes the reaction [Estradiol results in increased expression of CCN2 protein]	25616260
D004958	Estradiol	Estradiol results in increased expression of CCN2 mRNA	19484750
D000431	Ethanol	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D000431	Ethanol	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D000431	Ethanol	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D000431	Ethanol	CAT protein inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D000431	Ethanol	CAT protein inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D000431	Ethanol	[Ethanol co-treated with Thioacetamide] results in increased expression of CCN2 mRNA	21863215
D000431	Ethanol	Ethanol results in increased expression of CCN2 protein	19280452; 28962519;
D000431	Ethanol	[Ethanol results in increased expression of CCN2 protein] which results in increased abundance of Acetaldehyde	19280452
D000431	Ethanol	Fomepizole inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D000431	Ethanol	Fomepizole inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D000431	Ethanol	Vitamin D inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D000431	Ethanol	Vitamin D inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D000431	Ethanol	Ethanol results in increased expression of CCN2 mRNA	16098508
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of CCN2 mRNA	20170705; 26865667;
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of CCN2 mRNA	18936297
D005047	Etoposide	Etoposide results in increased expression of CCN2 mRNA	29397400
C063007	exoenzyme C3, Clostridium botulinum	exoenzyme C3, Clostridium botulinum inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]	15298857
C063007	exoenzyme C3, Clostridium botulinum	exoenzyme C3, Clostridium botulinum inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]	15298857
C545733	fatostatin	fatostatin inhibits the reaction [Glucose results in increased expression of CCN2 protein]	22031849
D017313	Fenretinide	Fenretinide results in increased expression of CCN2 mRNA	28973697
C056164	fenugreek seed meal	fenugreek seed meal inhibits the reaction [Streptozocin results in increased expression of CCN2 mRNA]	25057273
C056164	fenugreek seed meal	fenugreek seed meal inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	25057273
D005472	Fluorouracil	Fluorouracil affects the expression of CCN2 mRNA	15205334
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of CCN2	20938992
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CCN2 gene	20938992
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CCN2 mRNA	20938992
D000077604	Fomepizole	Fomepizole inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D000077604	Fomepizole	Fomepizole inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D004397	Fonofos	Fonofos results in increased methylation of CCN2 promoter	22847954
D005557	Formaldehyde	Formaldehyde results in increased expression of CCN2 mRNA	20655997; 23416264; 28937961;
D005620	Freund's Adjuvant	Freund's Adjuvant results in decreased expression of CCN2 mRNA	20846436
D005632	Fructose	betanin inhibits the reaction [Fructose results in increased expression of CCN2 protein]	25559852
D005632	Fructose	Fructose results in increased expression of CCN2 protein	25559852
C039281	furan	furan results in increased expression of CCN2 mRNA	27387713
C039281	furan	furan results in increased expression of CCN2 protein	27371368
D005742	Gasoline	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D005742	Gasoline	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D019833	Genistein	Genistein affects the expression of CCN2 mRNA	26865667
D019833	Genistein	Genistein results in decreased expression of CCN2 mRNA	20884965
C002963	geranylgeranyl pyrophosphate	geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]	15298857
D005944	Glucosamine	Glucosamine analog results in increased expression of CCN2 mRNA	21466783
D005947	Glucose	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D005947	Glucose	bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]	10026205
D005947	Glucose	Cadmium inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D005947	Glucose	CCL2 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]	21367880
D005947	Glucose	Glucose results in increased expression of CCN2 mRNA	10026205
D005947	Glucose	Glucose results in increased expression of CCN2 protein	19369054; 21367880;
D005947	Glucose	SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D005947	Glucose	Zinc inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D005947	Glucose	Aspirin inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]	14586741
D005947	Glucose	CCN2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]	21124846
D005947	Glucose	fatostatin inhibits the reaction [Glucose results in increased expression of CCN2 protein]	22031849
D005947	Glucose	Glucose results in increased expression of CCN2 mRNA	14586741
D005947	Glucose	Glucose results in increased expression of CCN2 protein	22031849; 26891083;
D005947	Glucose	HIF1A protein affects the reaction [Glucose results in increased expression of CCN2 protein]	26891083
D005947	Glucose	MIR217 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]	26891083
D005947	Glucose	Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]	26891083
D005947	Glucose	SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]]	26891083
D056604	Grape Seed Extract	Grape Seed Extract inhibits the reaction [Arsenic results in increased expression of CCN2 mRNA]	24348802
C511402	Grape Seed Proanthocyanidins	[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of CCN2 mRNA	24763279
C010176	halofuginone	halofuginone results in increased expression of CCN2 mRNA	17180598
C005499	honokiol	honokiol inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	21265825
C005499	honokiol	honokiol affects the expression of CCN2 mRNA	21265825
C005499	honokiol	honokiol inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	21265825
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of CCN2 mRNA	20044591; 23410634;
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of CCN2 protein	15147944
C031927	hydroquinone	hydroquinone results in increased expression of CCN2 mRNA	31256213
C492448	ICG 001	ICG 001 results in increased expression of CCN2 mRNA	26191083
C036619	idebenone	idebenone inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	28648635
D016285	Iloprost	Iloprost inhibits the reaction [2-Acetylaminofluorene results in increased expression of CCN2 mRNA]	15940639
C016517	indole-3-carbinol	indole-3-carbinol affects the expression of CCN2 mRNA	21396975
D007213	Indomethacin	Indomethacin results in increased expression of CCN2 mRNA	12077510
D000077146	Irinotecan	Irinotecan results in increased expression of CCN2 mRNA	20185912
C040507	isobutyl alcohol	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D007545	Isoproterenol	Isoproterenol results in increased expression of CCN2 mRNA	20003209
D007545	Isoproterenol	Isoproterenol results in decreased expression of CCN2 mRNA	24286936
D007545	Isoproterenol	Isoproterenol results in increased expression of CCN2 mRNA	24117263
D007545	Isoproterenol	Isoproterenol results in increased expression of CCN2 protein	24117263
D007545	Isoproterenol	Quercetin inhibits the reaction [Isoproterenol results in increased expression of CCN2 mRNA]	24117263
D007545	Isoproterenol	Quercetin inhibits the reaction [Isoproterenol results in increased expression of CCN2 protein]	24117263
D007545	Isoproterenol	Rutin inhibits the reaction [Isoproterenol results in increased expression of CCN2 mRNA]	24117263
D007545	Isoproterenol	Rutin inhibits the reaction [Isoproterenol results in increased expression of CCN2 protein]	24117263
C057531	jasplakinolide	jasplakinolide results in increased expression of and results in increased secretion of CCN2 protein	24040060
C057531	jasplakinolide	jasplakinolide results in increased expression of CCN2 mRNA	24040060; 25690654;
C057531	jasplakinolide	YAP1 protein affects the reaction [jasplakinolide results in increased expression of CCN2 protein]	24040060
C057531	jasplakinolide	jasplakinolide results in increased expression of CCN2 mRNA	25690654
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of CCN2 mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of CCN2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of CCN2 mRNA	25961927
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of CCN2 mRNA	25307878; 26752646;
C052787	kallidin, des-Arg(10)-	2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [kallidin, des-Arg(10)- results in increased expression of CCN2 mRNA]	15703175
C052787	kallidin, des-Arg(10)-	2',4'-dichlorobenzamil amiloride inhibits the reaction [kallidin, des-Arg(10)- results in increased expression of CCN2 mRNA]	15703175
D007657	Ketone Bodies	Ketone Bodies results in increased expression of CCN2 mRNA	16807920
C008261	lead acetate	lead acetate results in decreased expression of CCN2 mRNA	25270620
D000077339	Leflunomide	Leflunomide results in increased expression of CCN2 mRNA	28988120
D008070	Lipopolysaccharides	Lipopolysaccharides inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]	17965732
D008070	Lipopolysaccharides	aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein]	24412304
D008070	Lipopolysaccharides	[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein	24412304
D008070	Lipopolysaccharides	[[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein	24412304
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of CCN2 mRNA	17965732
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of CCN2 protein	17965732
D008148	Lovastatin	Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]	22712078; 28710503;
D008148	Lovastatin	Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]	22712078
C485003	LR-90	LR-90 results in decreased expression of CCN2 mRNA	18317729
C485003	LR-90	LR-90 results in decreased expression of CCN2 protein	18317729
C520284	Ly-364947	Ly-364947 inhibits the reaction [TGFB3 protein results in increased expression of CCN2 mRNA]	25566828
C032881	lysophosphatidic acid	lysophosphatidic acid results in increased expression of CCN2 mRNA	24706986
C032881	lysophosphatidic acid	N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA]	24706986
C032881	lysophosphatidic acid	lysophosphatidic acid results in increased expression of CCN2 protein	15200425
C032881	lysophosphatidic acid	Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]	15200425
C032881	lysophosphatidic acid	Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]	15200425
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of CCN2 mRNA	26378955
C025340	manganese chloride	manganese chloride results in increased expression of CCN2 mRNA	17467022
D008466	Mechlorethamine	Mechlorethamine results in increased expression of CCN2 mRNA	26273949
D008466	Mechlorethamine	Mechlorethamine results in increased expression of CCN2 protein	20883710
D017258	Medroxyprogesterone Acetate	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA	20823114
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
D008627	Mercuric Chloride	Mercuric Chloride results in decreased expression of CCN2 mRNA	16507785
D008694	Methamphetamine	Methamphetamine results in increased expression of CCN2 mRNA	29802913
D008715	Methionine	CCL2 protein inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]	20697377
D008715	Methionine	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA	18991162
D008715	Methionine	[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein	18991162
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of CCN2	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CCN2 gene	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CCN2 mRNA	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA	20697377; 22915297;
D008715	Methionine	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]	22915297
D008715	Methionine	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA]	18991162
D008715	Methionine	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein]	18991162
D008727	Methotrexate	CCN2 mRNA results in decreased susceptibility to Methotrexate	24154679
D008727	Methotrexate	Methotrexate results in decreased expression of CCN2 mRNA	17400583
D008727	Methotrexate	Methotrexate results in increased expression of CCN2 mRNA	19192274
C005219	methyl cellosolve	methyl cellosolve results in increased expression of CCN2 mRNA	21061450
C002950	methylformamide	methylformamide analog results in increased expression of CCN2 mRNA	17040096
C002950	methylformamide	methylformamide results in increased expression of CCN2 mRNA	17040096
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of CCN2 mRNA	23179753; 27188386; 28001369;
D008770	Methylnitrosourea	Methylnitrosourea results in decreased expression of CCN2 mRNA	16525678
D008775	Methylprednisolone	Methylprednisolone results in increased expression of CCN2 mRNA	19192274
D008790	Metoprolol	Metoprolol results in increased expression of CCN2 mRNA	22888001
D015735	Mifepristone	Mifepristone results in decreased expression of CCN2 mRNA	25972201
C540575	MK2i peptide	MK2i peptide results in decreased expression of CCN2 protein	20864298
C540575	MK2i peptide	MK2i peptide inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	20864298
C000622638	MLN7243	MLN7243 results in increased sumoylation of CCN2 protein	31285264
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in increased expression of CCN2 mRNA	16809437
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of CCN2 protein	24625837
C523799	MRK 003	CCN2 results in decreased susceptibility to MRK 003	19903844
C568376	MT19c compound	MT19c compound results in decreased expression of CCN2 mRNA	21781307
C500085	muraglitazar	muraglitazar results in decreased expression of CCN2 mRNA	21515302
D009151	Mustard Gas	Mustard Gas results in increased expression of CCN2 mRNA	16173061; 25102026;
D009151	Mustard Gas	Mustard Gas results in increased expression of CCN2 mRNA	27617619
C000589288	N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide	N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide results in decreased expression of CCN2 mRNA	24706986
C000589288	N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide	N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA]	24706986
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of CCN2 mRNA	22076105
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of CCN2 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of CCN2 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of CCN2 mRNA	25620056
C017096	n-butoxyethanol	n-butoxyethanol results in increased expression of CCN2 mRNA	19812364
C022838	nickel chloride	nickel chloride affects the expression of CCN2 mRNA	21496282
D009538	Nicotine	Nicotine results in increased expression of CCN2 protein	22691361
D009569	Nitric Oxide	[[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein	24412304
C007350	nitrofen	nitrofen results in decreased expression of CCN2 mRNA	20939759; 21258935;
C007350	nitrofen	nitrofen results in decreased expression of CCN2 protein	20939759; 21258935;
C007350	nitrofen	Tretinoin inhibits the reaction [nitrofen results in decreased expression of CCN2 mRNA]	21258935
C007350	nitrofen	Tretinoin inhibits the reaction [nitrofen results in decreased expression of CCN2 protein]	21258935
D018817	N-Methyl-3,4-methylenedioxyamphetamine	N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of CCN2 mRNA	20188158
C069741	norcantharidin	norcantharidin results in decreased expression of CCN2 mRNA	18176075
C069741	norcantharidin	norcantharidin results in decreased expression of CCN2 protein	18176075
C487513	NSC 23766	NSC 23766 inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]	28710503
C558013	NSC 689534	[NSC 689534 binds to Copper] which results in increased expression of CCN2 mRNA	20971185
C025589	ochratoxin A	ochratoxin A results in decreased expression of CCN2 mRNA	23358140
C025589	ochratoxin A	ochratoxin A results in increased expression of CCN2 mRNA	19717638
C510784	ormosil	[ormosil binds to Polyethylene Glycols] which results in decreased expression of CCN2 mRNA	24888373
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in increased expression of CCN2 mRNA	25729387
D000077150	Oxaliplatin	Oxaliplatin results in increased expression of CCN2 mRNA	25729387
D010100	Oxygen	NFE2L2 protein affects the reaction [Oxygen deficiency results in increased expression of CCN2 protein]	30096613
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to sulforafan] affects the reaction [Oxygen deficiency results in increased expression of CCN2 protein]	30096613
D010100	Oxygen	Oxygen deficiency affects the expression of CCN2 mRNA	17193925
D010100	Oxygen	Oxygen deficiency results in increased expression of CCN2 protein	24657099; 30096613;
D010100	Oxygen	sulforafan inhibits the reaction [Oxygen deficiency results in increased expression of CCN2 protein]	30096613
D010100	Oxygen	CCN2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]	21124846
D010100	Oxygen	Oxygen results in increased expression of CCN2 mRNA	22911455
D017239	Paclitaxel	[Cisplatin co-treated with Paclitaxel] affects the expression of CCN2 mRNA	20705681
D000073878	Palm Oil	Palm Oil results in increased expression of CCN2 mRNA	18042831
D010269	Paraquat	[CCN2 protein co-treated with Paraquat] affects the expression of MMP2 mRNA	26129822
D010269	Paraquat	[CCN2 protein co-treated with Paraquat] affects the expression of MMP9 mRNA	26129822
D010269	Paraquat	[CCN2 protein co-treated with Paraquat] affects the expression of TIMP1 mRNA	26129822
D010269	Paraquat	[Paraquat co-treated with TGFB1 protein] results in increased expression of CCN2 mRNA	26129822
D010269	Paraquat	Paraquat results in increased expression of CCN2 mRNA	15728566; 16767377; 20035857; 26129822; 27682480;
D010269	Paraquat	Paraquat results in increased expression of CCN2 protein	16767377; 20035857; 25815693; 27682480;
D010269	Paraquat	Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	20035857
D010269	Paraquat	Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	20035857
D010269	Paraquat	TGFB1 protein promotes the reaction [Paraquat results in increased expression of CCN2 protein]	27682480
D010269	Paraquat	Triamcinolone Acetonide promotes the reaction [Paraquat results in increased expression of CCN2 mRNA]	15728566
D010269	Paraquat	ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	25945502
D010269	Paraquat	Paraquat results in increased expression of CCN2 mRNA	12595580; 25945502; 26758514;
D010269	Paraquat	Paraquat results in increased expression of CCN2 protein	26758514
D010269	Paraquat	plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	26758514
D010269	Paraquat	plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	26758514
D010269	Paraquat	Paraquat results in increased expression of CCN2 mRNA	23433149
D010269	Paraquat	Paraquat results in increased expression of CCN2 protein	23433149; 25815693;
D010269	Paraquat	prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	23433149
D010269	Paraquat	prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	23433149
D010278	Parathion	Parathion results in increased methylation of CCN2 promoter	22847954
D052638	Particulate Matter	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D052638	Particulate Matter	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D052638	Particulate Matter	Particulate Matter results in increased expression of CCN2 mRNA	21708214
D020245	p-Chloromercuribenzoic Acid	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of CCN2 mRNA	26272509
D010431	Pentoxifylline	Pentoxifylline results in decreased expression of CCN2 mRNA	11788567
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in increased expression of CCN2 mRNA	27153767
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in increased expression of CCN2 mRNA	21251948
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of CCN2 protein	26879310
D010634	Phenobarbital	Phenobarbital results in decreased expression of CCN2 mRNA	19084549
D010634	Phenobarbital	Phenobarbital results in increased expression of CCN2 mRNA	19270015
D010656	Phenylephrine	Phenylephrine results in increased expression of CCN2 mRNA	15276029
D010656	Phenylephrine	Phenylephrine results in increased expression of CCN2 protein	15276029
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of CCN2 mRNA	26272509
D010696	Phloroglucinol	Phloroglucinol analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	26054450
D010795	Phthalic Acids	Phthalic Acids results in increased expression of CCN2 mRNA	21061450
D000077205	Pioglitazone	[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D000077205	Pioglitazone	Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]	20847119
D000077205	Pioglitazone	Pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	16484506
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CCN2 mRNA	19710929
C006253	pirinixic acid	pirinixic acid inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	19429239
C006253	pirinixic acid	pirinixic acid results in increased expression of CCN2 mRNA	18301758; 23811191;
D010894	Piroxicam	Piroxicam results in decreased expression of CCN2 mRNA	21858171
C442842	plant extract, Puerariae Radix	plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	26758514
C442842	plant extract, Puerariae Radix	plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	26758514
D010936	Plant Extracts	Plant Extracts results in decreased expression of CCN2 mRNA	23557933
D010938	Plant Oils	Plant Oils results in increased expression of CCN2 mRNA	23370395
C108953	platycodin D	platycodin D results in decreased expression of CCN2 protein	29595072
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA	29432896
D011092	Polyethylene Glycols	[ormosil binds to Polyethylene Glycols] which results in decreased expression of CCN2 mRNA	24888373
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of CCN2 protein	29309811
D011239	Prednisolone	Prednisolone results in increased expression of CCN2 mRNA	19192274
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in increased expression of CCN2 mRNA	28903501
D011374	Progesterone	Progesterone results in increased expression of CCN2 mRNA	23018184
D011374	Progesterone	CCN2 gene mutant form results in increased abundance of Progesterone	21868453
D011374	Progesterone	[CCN2 gene mutant form results in increased abundance of Progesterone] which results in increased expression of CASP3 mRNA	21868453
D011374	Progesterone	Progesterone affects the expression of CCN2 mRNA	17251523
D011374	Progesterone	Progesterone results in increased expression of CCN2 mRNA	22238285
C066229	prolinedithiocarbamate	prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	23433149
C066229	prolinedithiocarbamate	prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	23433149
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of CCN2 mRNA	24780913; 25825206;
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of CCN2 mRNA	27029645
C014175	pyrazolo(3,4-d)pyrimidine	pyrazolo(3,4-d)pyrimidine analog affects the expression of CCN2 mRNA	21152443
D011794	Quercetin	Quercetin results in decreased expression of CCN2 mRNA	21632981
D011794	Quercetin	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]	22915297
D011794	Quercetin	Quercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA]	22989100
D011794	Quercetin	Quercetin inhibits the reaction [Isoproterenol results in increased expression of CCN2 mRNA]	24117263
D011794	Quercetin	Quercetin inhibits the reaction [Isoproterenol results in increased expression of CCN2 protein]	24117263
D011794	Quercetin	Quercetin inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	15573758
D000077185	Resveratrol	Resveratrol results in decreased expression of CCN2 mRNA	23224687
D000077185	Resveratrol	Resveratrol affects the expression of CCN2 mRNA	17875610
D000077185	Resveratrol	Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]	26891083
D000077185	Resveratrol	SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]]	26891083
C116926	rofecoxib	rofecoxib inhibits the reaction [Carbon Tetrachloride results in increased expression of CCN2 protein]	17565644
D000077154	Rosiglitazone	[Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D000077154	Rosiglitazone	Rosiglitazone results in decreased expression of CCN2 mRNA	25572481
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 mRNA]	18991162
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCN2 protein]	18991162
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	19764552
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	19764552
C041376	rosmarinic acid	rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	28789951
C041376	rosmarinic acid	rosmarinic acid results in decreased expression of CCN2 mRNA	28789951
D012431	Rutin	Rutin inhibits the reaction [Isoproterenol results in increased expression of CCN2 mRNA]	24117263
D012431	Rutin	Rutin inhibits the reaction [Isoproterenol results in increased expression of CCN2 protein]	24117263
D012504	Saralasin	Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]	20035857
D012504	Saralasin	Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 protein]	20035857
C093642	SB 203580	SB 203580 analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	26054450
C093642	SB 203580	SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
C093642	SB 203580	SB 203580 results in decreased expression of CCN2 protein	20864298
D000068677	Sildenafil Citrate	PRKG1 protein promotes the reaction [Sildenafil Citrate inhibits the reaction [AGT protein modified form results in increased expression of CCN2 mRNA]]	25139994
D000068677	Sildenafil Citrate	Sildenafil Citrate inhibits the reaction [AGT protein modified form results in increased expression of CCN2 mRNA]	25139994
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of CCN2 mRNA	25351596; 27095093;
D019821	Simvastatin	geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]	15298857
D019821	Simvastatin	Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]	15298857; 15677772;
D019821	Simvastatin	Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]	15298857; 15677772;
D019821	Simvastatin	Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]	19080365
D019821	Simvastatin	Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein]	19080365
D019821	Simvastatin	Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]	15200425
D019821	Simvastatin	Simvastatin results in decreased expression of CCN2 mRNA	15200425; 19099753; 19659652;
D019821	Simvastatin	Simvastatin results in decreased expression of CCN2 protein	15200425; 19659652;
D020123	Sirolimus	Sirolimus results in increased expression of CCN2 mRNA	21865292
D012906	Smoke	Smoke analog results in increased expression of CCN2 mRNA	23155386
D012906	Smoke	Smoke analog results in increased expression of CCN2 protein	23155386
D012906	Smoke	Smoke affects the expression of CCN2 mRNA	23693141
C118258	SN50 peptide	SN50 peptide inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]	26581635
C017947	sodium arsenite	sodium arsenite results in increased expression of CCN2 mRNA	12377979; 25879800;
C017947	sodium arsenite	sodium arsenite affects the expression of CCN2 mRNA	16507464
C017947	sodium arsenite	candesartan cilexetil inhibits the reaction [sodium arsenite results in increased expression of CCN2 protein]	27889505
C017947	sodium arsenite	sodium arsenite results in increased expression of CCN2 protein	27889505
D012967	Sodium Dodecyl Sulfate	Sodium Dodecyl Sulfate results in decreased expression of CCN2 mRNA	25377654
C025399	sodium tungstate(VI)	sodium tungstate(VI) results in decreased expression of CCN2 mRNA	26164860
D053260	Soot	Soot results in increased expression of CCN2 mRNA	26551751
D000077157	Sorafenib	Sorafenib results in decreased expression of CCN2 mRNA	21360571
C060506	sphingosine 1-phosphate	sphingosine 1-phosphate results in increased expression of CCN2 mRNA	25690654
D013148	Spironolactone	Spironolactone inhibits the reaction [Aldosterone results in increased expression of CCN2 protein]	17278980
C517409	stattic	stattic inhibits the reaction [IL6 protein results in increased expression of CCN2 mRNA]	25740948
C517409	stattic	stattic inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCN2 mRNA]	25740948
D013311	Streptozocin	[Streptozocin co-treated with Dietary Fats] results in increased expression of CCN2 protein	24707343
D013311	Streptozocin	Streptozocin results in increased expression of CCN2	19657322
D013311	Streptozocin	Streptozocin results in increased expression of CCN2 protein	24967692
D013311	Streptozocin	sulforafan inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of CCN2 protein]	24707343
D013311	Streptozocin	sulforafan inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	24967692
D013311	Streptozocin	Acetylcysteine inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	17270171
D013311	Streptozocin	Aspirin inhibits the reaction [Streptozocin results in increased expression of CCN2 mRNA]	14586741
D013311	Streptozocin	Enalapril inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	21416479
D013311	Streptozocin	fenugreek seed meal inhibits the reaction [Streptozocin results in increased expression of CCN2 mRNA]	25057273
D013311	Streptozocin	fenugreek seed meal inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	25057273
D013311	Streptozocin	idebenone inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	28648635
D013311	Streptozocin	Streptozocin results in increased expression of CCN2 mRNA	10026205; 14586741; 25057273;
D013311	Streptozocin	Streptozocin results in increased expression of CCN2 protein	17270171; 19369054; 19895808; 21416479; 25057273; 28648635;
D013311	Streptozocin	XLF-III-43 inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	19895808
D013311	Streptozocin	Zinc inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	19369054
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of CCN2 mRNA	26378955
C016766	sulforafan	[NFE2L2 protein affects the susceptibility to sulforafan] affects the reaction [Oxygen deficiency results in increased expression of CCN2 protein]	30096613
C016766	sulforafan	sulforafan inhibits the reaction [Oxygen deficiency results in increased expression of CCN2 protein]	30096613
C016766	sulforafan	sulforafan inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of CCN2 protein]	24707343
C016766	sulforafan	sulforafan inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	24967692
C025462	sulindac sulfide	sulindac sulfide results in decreased expression of CCN2 mRNA	12734198
C025462	sulindac sulfide	sulindac sulfide results in increased expression of CCN2 mRNA	16184548
D000077210	Sunitinib	Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]	26581635
D000077210	Sunitinib	SN50 peptide inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]	26581635
D000077210	Sunitinib	Sunitinib results in increased expression of CCN2 mRNA	26581635
D013629	Tamoxifen	Tamoxifen affects the expression of CCN2 mRNA	20937368
D013629	Tamoxifen	Tamoxifen results in increased expression of CCN2 mRNA	25123088
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid results in decreased expression of CCN2 mRNA	15885361
C001803	tempol	tempol results in decreased expression of CCN2 mRNA	16685210
C012568	terbufos	terbufos results in increased methylation of CCN2 promoter	22847954
D020122	tert-Butylhydroperoxide	[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D020122	tert-Butylhydroperoxide	Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]	20847119
D020122	tert-Butylhydroperoxide	[Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide affects the expression of CCN2 mRNA	23410634
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA	20847119
D020122	tert-Butylhydroperoxide	[Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D020122	tert-Butylhydroperoxide	Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]	20847119
D013739	Testosterone	Testosterone results in increased expression of CCN2 mRNA	15788153
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of CCN2 mRNA	22298810
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA	19684285
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CCN2 mRNA	19684285; 20106945; 21632981; 26159488;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of CCN2 mRNA	20702594; 21570461; 28922406;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CCN2 mRNA	19770486; 19933214;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of CCN2 mRNA	15034205; 26290441;
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCN2 mRNA]	23196670
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CCN2 mRNA	21724226
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of CCN2 mRNA	23196670
D013752	Tetracycline	Tetracycline results in increased expression of CCN2 mRNA	16917069
D013853	Thioacetamide	[Ethanol co-treated with Thioacetamide] results in increased expression of CCN2 mRNA	21863215
D013853	Thioacetamide	TGFBR1 protein promotes the reaction [Thioacetamide results in increased expression of CCN2 mRNA]	28560358
D013853	Thioacetamide	Thioacetamide results in increased expression of CCN2 mRNA	28560358
D013853	Thioacetamide	Coffee inhibits the reaction [Thioacetamide results in increased expression of CCN2 protein]	22899499
D013853	Thioacetamide	Thioacetamide results in increased expression of CCN2 protein	22899499
C009495	titanium dioxide	titanium dioxide results in increased expression of CCN2 mRNA	27760801
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of CCN2 mRNA	29501877
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of CCN2 mRNA	27865774
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of CCN2 mRNA	27404394; 29505817;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of CCN2 mRNA	22761892
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of CCN2 mRNA	19332661
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of CCN2 protein	29177025
D014028	Tobacco Smoke Pollution	alpha-Fetoproteins inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CCN2 mRNA]	15994428
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of CCN2 mRNA	15994428
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in increased expression of CCN2 mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of CCN2 mRNA	25729387
D014212	Tretinoin	Tretinoin results in increased expression of CCN2 mRNA	23830798
D014212	Tretinoin	Tretinoin inhibits the reaction [nitrofen results in decreased expression of CCN2 mRNA]	21258935
D014212	Tretinoin	Tretinoin inhibits the reaction [nitrofen results in decreased expression of CCN2 protein]	21258935
D014212	Tretinoin	Tretinoin results in increased expression of CCN2 mRNA	20488242; 21258935;
D014212	Tretinoin	Tretinoin results in increased expression of CCN2 protein	21258935
C032910	triadimefon	triadimefon results in decreased expression of CCN2 mRNA	26705709
D014222	Triamcinolone Acetonide	Triamcinolone Acetonide promotes the reaction [Paraquat results in increased expression of CCN2 mRNA]	15728566
C012589	trichostatin A	trichostatin A results in increased expression of CCN2 mRNA	19606018; 26705709;
D014302	Trinitrobenzenesulfonic Acid	stattic inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCN2 mRNA]	25740948
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in increased expression of CCN2 mRNA	25740948
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of CCN2 mRNA	26179874
D000077288	Troglitazone	[Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA	20847119
D000077288	Troglitazone	Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]	20847119
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]	17056281
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]	17056281; 19429239;
D000077288	Troglitazone	Troglitazone results in decreased expression of CCN2 mRNA	25572481
D000077288	Troglitazone	Troglitazone results in increased expression of CCN2 mRNA	19140230
D014520	Urethane	Urethane results in increased expression of CCN2 mRNA	28818685
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid results in decreased expression of CCN2 mRNA	15885361
D014635	Valproic Acid	Valproic Acid affects the expression of CCN2 mRNA	25979313; 26072468;
D014635	Valproic Acid	Valproic Acid results in decreased expression of CCN2 mRNA	24935251
D014635	Valproic Acid	Valproic Acid results in decreased methylation of CCN2 gene	29501571
D014635	Valproic Acid	Valproic Acid results in increased expression of CCN2 mRNA	23179753; 27188386; 28001369; 29154799; 29501571;
D014635	Valproic Acid	Valproic Acid affects the expression of CCN2 mRNA	17292431; 26072468;
C066075	vanadium pentoxide	vanadium pentoxide results in decreased expression of CCN2 mRNA	17459161
C100058	vanillin	vanillin results in decreased expression of CCN2 mRNA	17178418
D001335	Vehicle Emissions	Vehicle Emissions results in decreased expression of CCN2 mRNA	19165385
D001335	Vehicle Emissions	Vehicle Emissions results in increased expression of CCN2 mRNA	23905969
D000077362	Verteporfin	Verteporfin inhibits the reaction [YAP1 protein results in increased expression of CCN2 mRNA]	29725256
D000077362	Verteporfin	Verteporfin results in decreased expression of CCN2 mRNA	29725256
D014747	Vinblastine	CCN2 protein affects the susceptibility to Vinblastine	16217747
C025643	vinclozolin	vinclozolin affects the expression of CCN2 mRNA	19015723
C025643	vinclozolin	vinclozolin results in decreased expression of CCN2 mRNA	23034163
D014750	Vincristine	CCN2 mRNA results in decreased susceptibility to Vincristine	24154679
D014800	Vitallium	Vitallium analog results in decreased expression of CCN2 mRNA	23825117
D014807	Vitamin D	Vitamin D inhibits the reaction [Ethanol results in increased expression of CCN2 mRNA]	19280452
D014807	Vitamin D	Vitamin D inhibits the reaction [Ethanol results in increased expression of CCN2 protein]	19280452
D024483	Vitamin K 3	Vitamin K 3 affects the expression of CCN2 mRNA	20044591; 23410634;
D000077337	Vorinostat	Vorinostat results in increased expression of CCN2 mRNA	27188386
C548351	XLF-III-43	XLF-III-43 inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	19895808
C108830	Y 27632	Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]	15200425
C526709	yishen huoxue decoction	yishen huoxue decoction results in decreased expression of CCN2 mRNA	17121042
D015032	Zinc	Zinc inhibits the reaction [Glucose results in increased expression of CCN2 protein]	19369054
D015032	Zinc	Zinc inhibits the reaction [Dietary Fats results in increased expression of CCN2 protein]	27370414
D015032	Zinc	Zinc inhibits the reaction [Streptozocin results in increased expression of CCN2 protein]	19369054

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0025	Alternative splicing
KW-0130	Cell adhesion
KW-1015	Disulfide bond
KW-0237	DNA synthesis
KW-0272	Extracellular matrix
KW-0325	Glycoprotein
KW-0358	Heparin-binding
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0732	Signal

Interpro

InterPro ID	InterPro Term
IPR006207	Cys_knot_C
IPR006208	Glyco_hormone_CN
IPR009030	Growth_fac_rcpt_cys_sf
IPR000867	IGFBP-like
IPR012395	IGFBP_CNN
IPR017891	Insulin_GF-bd_Cys-rich_CS
IPR000884	TSP1_rpt
IPR036383	TSP1_rpt_sf
IPR001007	VWF_dom

PROSITE

PROSITE ID	PROSITE Term
PS01185	CTCK_1
PS01225	CTCK_2
PS00222	IGFBP_N_1
PS51323	IGFBP_N_2
PS50092	TSP1
PS01208	VWFC_1
PS50184	VWFC_2

Pfam

Pfam ID	Pfam Term
PF00007	Cys_knot
PF00219	IGFBP
PF00090	TSP_1
PF00093	VWC